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Abbreviations 
Abs      antibodies 
AMI     acute myocardial infarction  
Anti-Pc IgM    IgM antibody to phosphorylcholine 
C1-inh     C1-Inhibitor 
CK     creatine kinase 
CPS     C-polysaccharide of pneumococci 
CRP     C-reactive protein 
CRs     complement receptors 
ELISA     enzyme-linked immunosorbent assay 
FcȖR     Fc gamma receptor 
HSA     human serum albumin 
IRI     ischemia reperfusion injury 
II/R     intestinal ischemia reperfusion  
LDH     lactate dehydrogenase 
LDL     low-density lipoprotein  
Lyso-Pc    lysophosphatidylcholine 
mAb      monoclonal antibody 
MAC     membrane attack complex  
MBL     mannose-binding lectin  
MFI     mean fluorescence intensity 
NHP     normal human plasma 
NRP     normal rat plasma 
oxLDL    oxidized LDL 
PAF     platelet activating factor  
Pc     phosphorylcholine 
PGE-2     prostaglandin E2 
sPLA2     secretory phospholipase A2
SRs     scavenger receptors 
TGF ȕ     transforming growth factor-ȕ
TNF Į     tumor necrosis factor- Į  
CHAPTER 1 
General introduction 
Introduction 
For decades, it is known that the innate immune system provides protection against invading 
pathogens. There is now much evidence that this system participates also in the recognition of 
self-antigens in eukaryotic organisms. Two proteins of the innate immune system, C-reactive 
protein (CRP) and natural anti-phosphorylcholine IgM antibody (anti-Pc IgM), share the 
ability to bind specifically to  phosphorylcholine (Pc). Pc is exposed on many pathogenic 
microorganisms, including bacteria, fungi and parasites. In mammals, Pc is normally only 
present on cell membranes after cell damage; furthermore it may be present in lipoproteins 
after oxidation. Indeed, CRP and anti-Pc IgM bind to Pc in the membranes of damaged cells 
and to oxidized lipoproteins, but not to either viable cells or native lipoproteins. In addition to 
their shared ability to bind to Pc, CRP and anti-Pc IgM can activate the complement system 
via the classical pathway upon ligand recognition. 
 CRP is the prototypical acute-phase protein in humans. CRP was discovered in 1930 
when it was shown that it could bind to C-polysaccharide of pneumococci [1]. It is now known 
that CRP specifically recognizes Pc [2]. However, CRP is not the only protein in plasma that 
binds to Pc. IgM antibody presents in sera of humans or animals binds also to Pc (anti-Pc 
IgM) [3-5]. Remarkably, in addition to their shared ability to bind to Pc, both proteins can 
activate complement upon ligand recognition [6-8]. Furthermore, CRP has been claimed to 
interact with Fc gamma receptors (FcȖR), particularly FcȖR II, although this interaction is 
weak and probably of limited biological significance [9-11]. IgM does not interact with FcȖR, 
preferring instead to bind to the poly-Ig R and to Fc Į/μ receptor [12,13]. There is accumulating 
evidence that complement activation by CRP and natural IgM antibody (IgM) is an important 
contributor to ischemia/reperfusion injury (IRI). In mouse models of IRI, a role of IgM herein 
has been postulated. In humans, both IgM and CRP play a role in complement activation after 
acute myocardial infarction (AMI). In rats, CRP-mediated complement activation seems to be 
involved in the increase of infarct size in rats subjected to coronary artery ligation, although it 
has been claimed that rat CRP (rCRP) does not activate rat complement. The relative 
contribution of both proteins in the development of IRI in humans and animals is still not fully 
elucidated. This chapter provides information about structural and functional aspects of CRP 
and anti-Pc IgM and their possible role in innate immunity, in atherosclerosis and in IRI. 
Below is summarized why nature has endowed us with two structurally different but 
functionally similar proteins. 
Structure of CRP and anti-Pc IgM 
CRP is a member of the pentraxin family and is characterized by a structure consisting of five 
non-covalently bound identical subunits (about 23 kDa). These subunits are arranged 
symmetrically around a central pore in an annular configuration. Each CRP subunit has a 
recognition face with a Pc binding site (consisting of two coordinated calcium ions) and an 
effector face with a C1q-binding site. The crystal structure of Pc bound to CRP has revealed 
that calcium ions and the residues Glu81 and Phe66 are important in ligand binding. Major 
protein-ligand interaction occurs between the protein-bound calcium ions and the phosphate 
groups of Pc and with Glu81 via the choline moiety [14]. The structure and topology of the C1q-
binding site has been defined by site-directed mutagenesis. This site is located at the shallow 
end of the cleft of the effector face, and the residues Asp112 and Tyr175 are critical for the CRP 
binding to C1q [15].
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 Anti-Pc IgM belongs to a group of plasma proteins, the immunoglobulin family [16]. 
Immunoglobulin molecules have a basic structure consisting of two identical light (smaller) 
and two identical heavy (larger) polypeptide chains linked together by disulphide chains. The 
nature of the antigen-binding sites of anti-Pc antibodies has been studied. The sequence Phe-
Tyr-Met-Glu found in the first complementary-determining region of the immunoglobulin 
heavy chain in 89 % of all anti-Pc Abs is involved in ligand-target interaction [17]. As in CRP, 
the residues Phe32 and Glu35 are involved in this interaction. 
The fact that the CRP-Pc interaction is calcium-dependent whereas anti-Pc IgM binds 
ligands independently of calcium (unpublished observation Diaz Padilla N.) suggests that 
these proteins use different mechanisms to interact with Pc, regardless of the fact that the 
same two amino-acid residues are present in both Pc-binding sites. IgM circulates in plasma 
usually as a pentamer consisting of five basic units, and it is one of the largest plasma proteins 
(970 kDa) [16]. Because of its pentameric structure, IgM has 10 antigen-binding sites per 
molecule. This is in contrast to CRP, which binds only five Pc groups. 
Phosphorylcholine: common ligand of CRP and anti-Pc IgM  
Pc is the name for the phosphorylated choline head group found in phospholipids of many 
prokaryotes, i.e. bacteria, and is almost universally expressed in eukaryotes. Pc contains both 
positive and negative charges and is overall, electrically neutral (zwitterionic) over a wide pH 
range [18]. In prokaryotes, Pc is bound both to carbohydrate and lipid components (figure 1).  
I       II 
Figure 1. Structure of Pc bound to carbohydrates and lipids component. I) Two Pc 
molecules are bound to CPS (teichoic acid) from streptococcus pneumoniae. In teichoic acid, 
the repeating units are linked by phosphodiester bonds between O5 of ribitol and O6 of the 
glucopyranosyl residue of adjacent units. A, D-Glcp; B, 2 acetamido-4 amino-2,4,6-trideoxy-
D-galactose;  C, D-GalpNAc; D, D-GalpNAc; E, D-ribitol (Fischer W.et al., 1993). II) Pc is 
bound to fatty acids to form phosphatidylcholine found in the cell membranes of prokaryotes. 
 Indeed, it has been shown that CRP and anti-Pc IgM bind to Pc present in the C-
polysaccharide from the cell wall of S. pneumoniae [1,19]. Interaction of CRP with Pc in 
lipopolysaccharides from Haemophilus influenzae, Pseudomona aeruginosa, Neisseria 
meningitides, Neiserria gonorrhoeae and Proteus morganii has been also reported [20-22]. In 
eukaryotes, Pc is the head group of the lipid phosphatidylcholine present in the outer leaflet of 
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the intact cell membranes and in lipoproteins such as low-density lipoprotein (LDL). 
However, Pc under normal conditions remains inaccessible, thereby preventing the interaction 
of CRP or anti-Pc IgM with viable cells and non-modified lipoproteins. Under certain 
conditions, Pc ligands are exposed, allowing their interaction with Pc-binding proteins (Table 
1).  
Table 1. Binding specificities of CRP and anti-Pc IgM 
                CRP       Anti-Pc IgM    
Pc on    
CPS (S. pneumoniae)   +++    +++     
LPS (H. influenzae)   +++    +++    
EAC       ?    +++    
LAC or NC     +++    +++    
OxLDL    +++    +++    
Oxidized Ptc    +++    +++    
Staining of atheroma   +++    +++     
AMI     +++    +++    
Pc: phosphorylcholine; CPS: C-polysaccharide of pneumococci; LPS: lipopolysaccharide; 
EAC: early apoptotic cells; LAC: late apoptotic cells; NC: necrotic cells; OxLDL: oxidized 
low-density lipoprotein; Ptc: phosphatidylcholine; AMI: acute myocardial infarction. 
Flip-flop and oxidation of cell membranes 
Most cells are characterized by a marked asymmetry in the distribution of the phospholipids 
composing the plasma membrane. Most of the phosphatidylethanolamine (PE) and nearly all 
phosphatidylserine (PS) molecules are localized in the inner leaflet, and the majority of 
sphingomyelin and phosphatidylcholine (PC) are in the outer leaflet of the membrane. This 
asymmetry is maintained by an aminophospholipid translocase that sequesters PS and to 
lesser extent PE in the inner leaflet of the plasma membrane bilayer [23]. When cells undergo 
apoptosis, and upon depletion of ATP as seen during ischemia, this asymmetry is not 
maintained, resulting in exchange of phospholipids between the inner and outer leaflets with 
the exposition of PS and PE, the so-called flip-flop of the membrane [24]. At sites of tissue 
injury, polymorphonuclear leukocytes are recruited and activated among others by 
inflammatory cytokines [25]. Activated cells generate reactive oxygen species, leading to 
oxidation of the phospholipids, which may further disturb the tight package of lipid bilayer. 
Because of the loss of the membrane integrity, efficient hydrolysis of the phospholipids by 
cytosolic and secreted phospholipases A2 is facilitated, thus generating lysophospholipids of 
PC, PE and PS. Binding sites for CRP and anti-Pc IgM, lysophosphatidylcholine, are 
generating in the outer leaflet of the jeopardized membranes [26, 27], (figure 2).  
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Figure 2. Proposed mechanism for CRP and anti Pc-IgM binding to Pc on damaged cell 
membranes. In intact cells, sphingomyelin and phosphatidylcholine are present in the outer 
leaflet of the membrane. After apoptosis and/or upon depletion of ATP, the distribution of the 
phospholipids in the membrane is exchanged and PS and PE are present in the outer leaflet 
(flip-flop). Because of the flip-flop and oxidation of the phospholipids, the tight package of 
lipid bilayer is lost and the phospholipids are susceptible to hydrolysis by phospholipases A2. 
In this way, lysophosphatidylcholine is generated in the outer leaflet of the membrane, thus 
creating binding sites for CRP and IgM. 
 In vitro it has been demonstrated that CRP and anti-Pc IgM bind to Pc exposed in the 
membrane of apoptotic cells [8, 28,29]. In vivo evidence of IgM binding to Pc on damaged cells 
is supported by observation of decreased levels of these Abs in plasma from patients with skin 
tumors after treatment with tumor necrosis factor-alpha (TNF Į). Massive death of the 
malignant and endothelial cells is observed following treatment [30,31]. CRP and IgM are also 
deposited in heart specimens from patients who have died from acute myocardial infarction. 
The deposition pattern of IgM in the tissue is similar to that of CRP, suggesting that both 
proteins recognize similar epitopes (Pc) in the ischemic heart [32]. Indeed, a considerable 
amount of lyso-phospholipids is generated in the infarcted myocardium [33]. 
Oxidized phospholipids on lipoproteins  
Both proteins are also able to bind to Pc on LDL, but only after oxidation. In human 
atherosclerotic lesions, which are known to contain high amounts of oxidized phospholipids, 
positive staining for CRP has been found [34,35]. In addition, anti-Pc IgM Abs are also 
deposited in atherosclerotic lesions of rabbits and mice [19,36,37].
  
Phosphatidylcholine                          CRP      
Sphingomyelin 
Phosphatidylserine        Anti-Pc     IgM  
Phosphatidylethanolamine 
Flip-flop/ oxidized cell  membrane 
 Apoptosis / ATP  
Oxygen free radicals 
Intact cell membrane 
iPLA2 & sPLA2 
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Functional properties of CRP and anti-Pc IgM 
CRP is produced by hepatocytes in response to an infection and/or an inflammatory stimulus 
[38]. The regulation of its synthesis varies among species. In humans and rabbits, normal levels 
of CRP are very low (about 1 mg/L) and can increase up to 1000-fold during an acute-phase 
response [39,40]. In rats, CRP is a minor acute-phase protein, with normal levels of about 500 
mg/L, increasing at most 2-fold during infection and/or inflammation [41]. CRP levels in mice 
reach a maximum expression of 2-3 mg/L in the acute phase [11,42], (table 2). 
Table 2. Behaviour of CRP and anti-Pc IgM in different species   
Species  CRP   CRP   anti-Pc IgM  
  normal plasma acute-phase plasma  normal plasma  
  (mg/L)   (mg/L)   (mg/L)    
Man   1    1000   1.5  
Rat  500   1000    ?  
Rabbit  1   1000   ? 
Mouse   <0.02    2-3    0.05-5 
  
 IgM produced by different types of cells can be found in the circulation of normal 
mice, rats and humans. Natural IgM is produced mainly by the B1 subset of B-lymphocytes 
without antigen exposure, and antigen-induced IgM is produced by conventional B-2 cells in 
the presence of an antigen [43]. B1 cells, characterized by the CD5 marker, are already present 
in the peritoneal cavity during fetal and neonatal life and produce IgM without antigen 
stimulation [44]. However, foreign antigens can stimulate B1 cells after complement 
activation. Complement receptors (CRs) CR1 and CR2 on B1 cells bind to activated 
complement fragments attached to an antigen-transmembrane IgM antibody complex. It 
seems that co-ligation of CR2 with the B-cell receptor leads to activation of the cells and 
enhances antibody production [45], (figure 3). 
Natural IgM antibodies are polyreactive, since they can bind to several unrelated 
antigens with low affinity, such as nucleic acids, carbohydrates and phospholipids [44]. Natural 
IgM antibodies to Pc are present in normal serum of human, rat and mice [3-5]. In humans and 
mice these antibodies are frequently of the T15 idiotype (id).T15 id is characterized by a 
canonical VHDJH-Vț22Jț5 H+L Ig chain combination. This combination of H+L chains was 
initially identified in an IgA protein secreted by the plasmacytoma line TEPC-15 and defines 
the T15 idiotype [37,46].
The contribution of both CRP and anti-Pc IgM to Pc binding varies in different species 
in the normal situation and during acute-phase reaction (APR). In normal human and rabbit 
plasma with similar levels of CRP and anti-Pc IgM, IgM could be the predominant ligand to 
Pc binding (human anti-Pc IgM is about 1.5 μg/mL, Diaz Padilla N.; unpublished 
observation). We suggest that the increase in CRP of about 1000-fold during APR in both 
species makes CRP the dominant Pc-binding protein during inflammation, infection, and 
tissue damage. In mice with high IgM and low CRP levels, IgM will be the dominant protein, 
whereas in rats with high CRP levels and low IgM, CRP will be the dominant factor. 
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Figure 3. Schematic view of the role of the complement receptors in the production of 
natural IgM by B1 cells. A) Natural IgM is produced by B1 cells in absence of antigen. B)
Immune complexes formed by antigen (Ag) and transmembrane IgM (IgM) on the cell surface 
are suggested to lead to complement activation. Activated complement fragments such as C3d 
bind to complement receptors, i.e. CR2 on the cell membrane. The cross-linking of the 
complement receptor and B-cell antigen-receptor triggers proliferation of B1 cells leading to 
IgM natural antibody production. 
Complement activation by CRP and anti-Pc IgM  
Principal biological consequences of CRP are largely determined by interaction with C1q 
upon Pc recognition, thereby activating the complement system [47]. Human, rabbit and rat 
CRP are able to activate complement via the classical pathway [7,48,49]. Activation of 
complement leads to either direct (via membrane attack complex, MAC) or indirect (via CRs 
on macrophages/dendritic cells), target destruction [50,51]. Complement activation triggered by 
CRP leads to deposition of activated complement components C4b, C3b, and C3bi on 
microbes, damaged cells, or OxLDL. Gershov et al. have demonstrated that CRP binding to 
apoptotic cells results in activation of early complement cascade events and in reduction of 
MAC assembly on apoptotic cells by recruitment of Factor H [52]. Factor H accelerates the 
decay of the C3 and C5 convertases. The decreased formation of MAC in membranes 
prevents leakage of intracellular constituents into the environment and in that way prevents 
increase of inflammation. Indeed, early complement components such as C4b, C3b/bi likely 
recruit and promote the removal of apoptotic cells by the CRs CR1, CR3 and CR4 on 
macrophages and dendritic cells. The uptake of complement-coated particles by CRs induces 
the production of non-inflammatory components such as TGFȕ, PGE2, and PAF [53]. The 
uptake by macrophages and dendritic cells of necrotic cells, intracellular contents, OxLDL, 
and pathogens is enhanced through ligand binding to scavenger receptors. Macrophages 
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transformed to foam cells release proinflammatory cytokines, i.e. TNFĮ, IL-1, IL-12      
(figure 4). 
3URLQIODPPDWRU\
TGF-Į
IL-12
IL-1
necrosis CD36
FcȖ
SR-A
)RDPFHOOVOO
TGF-ȕ
PAF
Prostaglandin E2
CR1, CR2, CR3 Mĳ
Mĳ
PC
Y
Y
Y
$QWLLQIODPPDWRU\
Y
Y
Y Y
Y
Y
Figure 4. Proposed consequences of CRP-and anti-Pc IgM-mediated complement 
activation in the removal of Pc ligands. Phosphorylcholine (Pc-containing component) is 
present in pathogens and in altered self-molecules (apoptotic or necrotic cells or OxLDL). In 
the normal situation, CRP and IgM bind Pc followed by complement activation. Complement 
components are deposited on pathogens and altered self- molecules. Complement receptors 
CR1, CR2, and CR3 on macrophages and dendritic cells bind complement-coated molecules. 
Immunosuppressive components, i.e. PAF, TGFȕ and Prostaglandin E2 are secreted and 
promote the clearance in a non-inflammatory fashion. In situations of low CRP and IgM 
levels, altered self-molecules or pathogens are not efficiently phagocytosed. Apoptotic cells 
may undergo secondary necrosis and intracellular contents are released. The uptake by 
macrophages and dendritic cells of necrotic cells, intracellular contents, OxLDL, and 
pathogens is through the scavenger receptors (CD36 and SR-A). It induces the release of 
proinflammatory cytokines i.e. TNFĮ, IL-1, IL-12. In addition, IgG could recognize Pc on 
these components, which are taken up via FcȖR on phagocytic cells. Phagocytosis via FcȖR or 
scavenger receptors (SR) leads to an inflammatory reaction. In the presence of low amounts 
of complement-regulatory proteins, complement activation mediated by IgM may lead to 
pronounced MAC formation. MAC inserted in the cell membrane results in cell death and 
necrosis with release of intracellular contents. 
Complement 
Y Anti-Pc IgG 
CRP 
receptors Anti-Pc IgM 
Pc containing component 
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 Anti-Pc IgM is also able to activate the classical pathway of the complement system 
after binding to Pc in microbes, and in altered self-molecules [8,29,54,55]. While one molecule of 
IgM can lyse a red blood cell, approximately a thousand IgG molecules are required to 
accomplish the same [56]. Because IgM is the most potent complement activator, it is expected 
that anti-Pc IgM-mediated activation may lead to increased MAC formation and to cell death.  
It has been shown that anti-Pc IgM-mediated activation is responsible for deposition of early 
complement components, i.e. C3b/bi, on the membrane of apoptotic cells [8]. However, 
substantial deposition of MAC after this activation has not been reported.   
 We suggest that this type of complement activation by both molecules, i.e. limited to 
generation of early components with reduced amounts of late complement components, may 
lead to efficient opsonization and removal, and is not a strong stimulus for inflammation.   
CRP and anti-Pc IgM in the innate immune response 
Nearly 20 years ago, it was demonstrated that human CRP mediates protection from S.
pneumoniae.  Overall survival of mice infected with S. pneumoniae increased when the mice 
were treated with human CRP [57,58]. The requirement of complement for the protective effect 
of CRP was demonstrated in mouse models. The protective effect of injected CRP to wild 
type, FcȖR, FcȖR IIb and FcȖR III-deficient infected mice was abrogated by complement 
depletion with cobra venom factor. In addition, CRP failed to protect C3- or C4-deficient 
mice from pneumococcal infection [11]. It has also been suggested that CRP can bind to FcȖR I 
and FcȖR II on leukocytes [9,10]. This binding results in increased production of the early 
protective cytokines TNF-Į and IL-1ȕ in response to S. pneumoniae [59]. However, Saeland et 
al. have reported that CRP does not bind to FcȖR IIa [60]. They claim that earlier findings were 
obtained because CRP-detecting IgG1 Abs may interact via the Fc portion with the FcȖR. 
Saeland et al. used F(ab’)2 fragments of the mouse IgG1 anti-CRP Ab. The presence of 
impurities in insufficiently purified CRP preparations could explain previous findings of 
interactions between CRP and IgG receptors [61]. Finally, gamma-chain-deficient mice, which 
lack most effector functions of FcȖR, are protected against pneumococcal infections after CRP 
injection, suggesting that the interaction of CRP with these receptors is not of essential 
importance for the antibacterial effects of CRP [11]. Thus, at present there is no convincing 
evidence for involvement of FcȖR in the protective effect of CRP in microbial infections. It is 
therefore likely that the protective effector functions of CRP against bacterial infection result 
from activation of complement by CRP bound to the bacteria [11; 62].
Notably, protection to pneumococcal infection by human CRP-mediated complement 
activation has been demonstrated in mice, which makes extrapolation to physiologic relevance 
in humans difficult. Indeed, recently it has been shown that protection to pneumococcal 
infection by CRP-mediated complement activation does not occur via the classical pathway. 
Notably, human CRP does not interact with mouse C1q [63]. Thus, the demonstration of a 
protective role of human CRP in this model remains challenging. 
 Like CRP, anti-Pc IgM confers protection against pneumococcal infection, which has 
been demonstrated in mouse models of infection. Immunocomprimised CBA/N mice (xid), 
which do not produce Abs against a group of thymus- independent antigens, have longer 
survival times following pneumococcal infection if IgM from normal mouse sera or anti-Pc 
IgM mAb is administered prior to the challenge [64]. The specificity of these Abs involved in 
protection is supported by the suppression of T15 id with anti-T15, or target deletion of the 
VH1 gene increases mortality [57,65]. The protective role of anti-Pc IgM is mediated by its 
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ability to activate the complement system and through interaction with the FcĮ/ȝ receptor. 
The increased survival after pneumoccal infection in mice conferred by anti-Pc IgM was 
abrogated after complement depletion with cobra venom factor, demonstrating the crucial role 
of complement [11,55]. In contrast to IgG and IgE, which interact with FcȖR and mediate a wide 
range of immune responses such phagocytosis, Ab-dependent cytotoxicity, antigen 
presentation and the production and secretion of many cytokines and chemokines [16] involved 
in protection, IgM does not interact with these receptors. In vitro experiments have shown that 
labelled immune complexes composed of IgM and S. aureus are endocytosed by B cells. The 
preincubation of B cells with rat anti-mouse FcĮ/ȝ receptor antibody blocked the endocytosis 
of the immune complexes. Thus, this receptor appears to mediate endocytosis of IgM-coated 
bacteria and may be involved in protection [13].
CRP and anti-Pc IgM in cardiovascular disease 
Perceptions of CRP as a predictor of coronary heart disease in the healthy population have 
changed. In publications before 2000, elevated levels of CRP were considered an independent 
risk factor. In healthy individuals with CRP base-line values higher than 3 mg/L, the relative 
risk for coronary disease was increased about three-fold [66, 67]. However, recent data show that 
the predictive value of CRP for coronary disease is lower. After adjustment for other 
cardiovascular risk factors, such as age, sex, and socioeconomic status, the risk is reduced to 
1.45 [68]. The pathophysiogical mechanisms demonstrating association between CRP and 
coronary disease are not completely clear. Likely, slightly elevated levels of CRP already 
found in healthy people may be associated with more atherosclerosis, a risk factor for 
coronary disease [69]. Indeed, atherosclerotic lesions rich in foam cells secrete IL-1 and IL-6, 
stimuli for CRP production [70,71].
Studies indicate that CRP may have both pro- and anti-atherogenic properties in 
atherosclerosis [34;72,73]. The anti-atherogenic property is mediated by its ability to activate the 
complement and to inhibit the OxLDL uptake via scavenger receptors (SRs). The 
colocalisation of CRP with MAC, enzymatically remodelled LDL, C3d and factor H in the 
intima of the arterial wall suggests that human CRP might activate the complement in human 
arteries. The fact that human CRP was deposited in a more extensive area than MAC, 
suggests that the activation is limited to the early complement components [34,74]. This was 
confirmed in vitro, since incubation of enzymatically remodelled LDL with human CRP 
generated substantial amounts of C3b, C3c and C4c, and minimal amounts of the MAC [75]. 
Thus, lipid particles may be taken up in a non-inflammatory fashion via CR, preventing their 
capture by the SRs. In addition, CRP inhibits the uptake of OxLDL by SR. SR class A-I/II and 
CD36 on macrophages are the principal receptors responsible for the uptake of OxLDL [76,77]. 
It has been shown that the uptake of OxLDL is mediated upon recognition of Pc by CD36. 
Following the uptake, macrophages transform into foam cells, and release pro-inflammatory 
cytokines and matrix metalloproteinases, which contributes to atherosclerosis [78]. In vitro, it 
has been shown that CRP inhibits both the binding and the degradation of OxLDL by murine 
macrophages and by CD36-transfected cells [79].
The pro-atherogenic property of CRP is explained by the interaction with FcȖR. 
Zwaka et al., reported that CRP could mediate the uptake of native LDL through FcȖRIIA 
(CD32) on human macrophages [80]. CRP co-incubated with LDL was added to macrophages 
in the presence of normal or inactivated serum. Co-localization of CRP, CD32 and LDL was 
evident exclusively in the presence of normal serum. As mentioned previously, CRP binds 
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only to modified and not to native LDL [28,81]. Therefore, spontaneous oxidation of LDL by air 
during the experiments, for example, and not during anti-oxidant conditions, may explain the 
results of Zwaka et al. Thus, CRP cross-linking of FcȖR during OxLDL uptake may lead, like 
cross-linking of the receptor by IgG, to the production of pro-inflammatory cytokines by 
activated macrophages [16].
Most published studies describe an association of anti-OxLDL Abs and cardiovascular 
disease. It is known that part of these Abs recognize Pc exposed on the oxidized molecule. An 
inverse relation between IgM titers to OxLDL and the develop of atherosclerosis has been 
reported [82,83]. Notably, we found no association between anti-Pc IgM titers at base line and 
occurrence of AMI in a prospective cohort of healthy people who developed AMI 
(unpublished Boekhorst, Diaz Padilla et al., 2004).
 The role of anti-Pc IgM T15 Abs on atherosclerosis has been studied in mouse models 
[19,37]. Mice deficient for the LDL receptor (Ldlr-) or apoplipoprotein E-null (Apoe-/-) mice, 
which develop extensive atherosclerosis after feeding with a cholesterol-rich diet, have been 
used. The immunization of cholesterol-fed Ldlr- mice with a pneumococcal preparation 
induced high titers of anti-Pc IgM T15, which in turn reduced progression of atherosclerosis 
[19]. In addition, passive immunization with an anti-Pc IgM mAb reduced accelerated vein 
graft atherosclerosis in Apoe -/- mice [84].
The anti-atherogenic property is explained by the ability of anti-Pc IgM T15 Ab to 
block the uptake of OxLDL by macrophages and their transformation into foam cells [37,85]. 
Pooled plasma from mice immunized with pneumococci, with high levels of Abs to OxLDL, 
was considerably more effective in blocking the binding of OxLDL to macrophages compared 
with the plasma from control mice [19]. Thus, once atherosclerotic lesions are induced, the 
endothelial barrier is destroyed and IgM Abs can gain access to the subintimal space and bind 
to OxLDL, thus forming immune complexes. The formation of immune complexes in the 
lumen and in the subintimal space of the blood vessel might block atherogenesis [78], (Figure 
5). Significantly increased levels of IgM-OxLDL immune complexes were measured in the 
plasma of the mice after pneumococcal immunization [16,19].
Anti-Pc IgM T15 is deposited in the atherosclerotic lesions, and their binding to 
OxLDL may trigger complement activation [19,36,37]. However, studies on complement 
activation triggered by Abs on the plaques and the role of this mechanism have not been 
reported.  
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Figure 5. Proposed role for phosphorylcholine-specific autoantibodies in slowing down the
progression of atherosclerosis. Atherosclerotic plaque formation in the blood vessel wall is 
initiated through uptake of LDL from blood by endothelial cells, and oxidation of LDL by 
reactive oxygen species within the vessel wall. Uptake of OxLDL by macrophages through 
scavenger receptors (such as CD36 and SR-A) leads to macrophage transformation into lipid-
laden, activated foam cells. In addition, foam cells produce large quantities of 
myeloperoxidase, an enzyme that produces reactive oxygen species, thereby stimulating 
oxidation of LDL and further promoting the vicious cycle. The production of IgM-specific Abs 
increases during atherogenesis (and is enhanced by pneumococcal vaccination). These Abs 
may be able to cross the endothelial barrier to reach the atherosclerotic lesion. There, they 
bind to antigens on the surface of OxLDL, forming immune complexes and blocking the 
uptake of OxLDL by macrophages. In addition, phosphorylcholine-specific IgM may bind 
OxLDL in the circulation, facilitating its clearance and making it unavailable for plaque 
formation [78].
Reprinted with permission from Nature Medicine 9, 641 - 642 (2003). 
CRP and natural IgM antibody in ischemia reperfusion injury 
Restoration of blood flow (reperfusion) to previously ischemic tissue triggers an inflammatory 
process, which damages the jeopardized tissue, a phenomenon known as ischemia reperfusion 
injury (IRI). It is a common pathophysiological event and a source of mortality in clinical 
conditions such as AMI, stroke, gut ischemia, organ transplantation, and cardiopulmonary 
bypass. Several inflammatory mediators have been implicated in IRI, including products from 
polymorphonuclear neutrophilic granulocytes, reactive oxygen species, and complement 
fragments [25]. Complement activation is a proposed essential step in ischemia/reperfusion-
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mediated inflammation, because complement inhibition and complement deficiency 
considerably attenuate irreversible injury [86-88]. However, the specific complement pathways 
involved remain unclear. All three complement pathways: the classical, the alternative, and 
MBL-dependent pathway, may be involved in the development of IRI, depending on the 
model, the tissue, and the time course of inflammation [89-91]. It has been shown in various 
clinical settings and in animal models of ischemia and reperfusion that CRP and natural IgM 
Abs are major mediators of IRI. Part of their deleterious effects has been attributed to their 
ability to activate the classical pathway of the complement system [91-93].
The involvement of CRP-mediated complement activation to the pathogenesis of 
disease during AMI has been demonstrated in a rat model. The intraperitoneal injection of 
human CRP after ligation of the coronary artery enhanced infarction size by 40 % and this 
enhancement of infarct size was completely prevented by in-vivo complement depletion [93]. 
In contrast, a recent study described that human CRP injection into rats after occlusion of the 
middle cerebral artery enhanced infarct size in a non-complement-mediated fashion [94]. 
Systemic complement depletion with cobra venom factor in these rats did not affect cerebral 
infarct size, indicating that circulating complement does not contribute to injury in this model. 
It could be suggested that another “pathogenic mechanism” of CRP may be involved in this 
increase. However, the increase in infarct size observed in the treated CRP animals showed a 
borderline difference compared with the albumin-treated rats, making it difficult to draw a 
conclusion from this study.  
 In human myocardial infarction as well as in the AMI rat model, colocalization of 
CRP with complement was observed in ischemic tissue [95]. This initial finding suggested that 
human CRP could activate the complement system in human AMI similar to its role in the 
experimental model. A further study demonstrated that human CRP is able to activate locally 
the complement system, since CRP-complement complexes, specific makers for CRP 
activation, were measured in homogenates prepared from infarcted human myocardium [96]. 
However, in humans no correlation between the extent of CRP and complement deposition 
and infarct size has been found [97]. So far, it is not known to what extent CRP contributes to 
infarct size in humans.  
 The development of non-complement-activating Abs against Pc that prevent the 
binding of CRP to the ischemic cells may provide further insight in the role of CRP and may 
also provide a therapy for reducing IRI. Human mAb of the IgG4 subclass could be useful in 
humans for therapeutic purposes because they are unable to significantly activate the 
complement system [16]. The cross-reactivity of such Abs with vital cells must be investigated. 
Furthermore, modified CRP molecules, able to bind to the appropriate ligand on the ischemic 
cells but not to activate complement, could provide another therapeutic approach in reducing 
injury after ischemia and reperfusion. Observations in mouse models have revealed that 
natural IgM Abs may be involved in the pathogenesis of IRI [86,91,98-100]. The identification of 
the neo-antigen(s) exposed or expressed by the ischemic cells and the specificity of IgM are 
still under investigation. Initial experiments with mice that lack all classes of Abs, RAG-1 -/- 
and RAG- 2 -/-, have revealed that these mice develop less IRI than wild-type mice. The 
administration of normal mouse sera and/or purified IgM to these mice in a hind limb or 
intestinal model of IRI, respectively, restored the damage to the levels observed in wild-type 
mice [86,91]. Following reconstitution, IgM and C3 were deposited on the endothelium of the 
ischemic reperfused mice but absent in sham controls. Knockout mice deficient in C4 (C4-/-) 
were found to be equally protected from local injury as were mice deficient in C3 (C3-/-) in 
both models of ischemia and reperfusion. These data demonstrate that the dependence on 
complement is via the classical pathway and support the role of natural Abs- mediated injury.  
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 Further studies with CR2-deficient (CR2-/-) mice confirmed natural IgM to be 
involved in the reperfusion injury. These mice lack CR2, resulting in a decreased repertoire of 
CD5+B-1 cells, and they are protected from IRI. Indeed, infusion with natural IgM purified 
from B-1 cells restored the injury to the levels observed in the wild-type mice in models of 
intestinal IRI. In contrast, reconstitution with pooled murine IgG alone did not restore 
histological injury but enhanced neutrophil infiltration when combined with IgM. C3 was 
exclusively deposited in the intestines of mice subjected to ischemia and reperfusion and 
treated with IgM. Therefore, IgM was the most potent complement-fixing isotype in this 
model, and responsible for IRI [101].
More recently, a mAb IgM from a specific clone (CM-22; IgMCM-22) of B-1 cells has 
been described that can restore injury in mice subjected to skeletal and intestinal IRI [99,100]. A 
protein of high molecular mass of about 250 KDa co-precipitated with IgMCM-22. Analysis of 
this high-molecular-mass band yielded peptide sequences homologous to nonmuscle myosin 
heavy chain (NMHC) type II A and C. A highly conserved region within both isoforms of 
NMHC has been identified as the target for IgM CM-22 and initiation of the injury in murine 
models of skeletal and intestinal ischemia and reperfusion. A synthetic peptide of 12 amino 
acids, representing the conserved region of NMHC was synthesized (P8). P8 bound IgMCM-22
in vitro and blocked IRI in the two distinct tissues. Furthermore, IgMCM-22 and C4 colocalized 
in the intestinal tissue after ischemia and reperfusion, and this deposition correlated with the 
pathology. It indicates that the pathogenic property of this IgM is mediated by its ability to 
activate the classical pathway of complement [100].
Conclusions 
CRP and anti-Pc IgM, two structurally different proteins of the innate immune system, share 
the ability to bind to Pc in heterologous and altered self-molecules. Both proteins are able to 
protect against infections, likely through their ability to activate the complement system via 
the classical pathway. The protective role of human CRP has been demonstrated in 
heterologous systems. Surprisingly, it has recently been reported that human CRP does not 
interact with mouse C1q. Further studies with mouse, rabbit and rat CRP in autologous 
systems are warranted to elucidate the role of complement in protection against infection in 
this system. There is evidence for a beneficial role of CRP and anti-Pc IgM in atherosclerosis. 
The binding of IgM and CRP to Pc residues on OxLDL blocks its uptake by SR on 
macrophages. This may prevent the transformation of macrophages into lipid-laden, activated 
foam cells, which promote the pro-inflammatory milieu in the atherosclerotic plaques. Studies 
on depositions of complement proteins suggest that CRP-mediated complement activation 
leads to reduced generation of MAC, which may also be beneficial. Further studies should 
shed more light on the role of CRP and anti-Pc IgM-mediated complement activation and 
atherogenesis. It seems that both proteins have survived in the evolution by the two actions 
mentioned above: protection against infection by Pc-containing microorganisms and clearance 
of oxidatively altered self-molecules. However, considerable evidence now points to an 
important role for CRP and natural IgM Ab in the pathogenesis of IRI. Ischemia leads to the 
exposition of “altered phospholipids” and new proteins on the cell membranes, which are 
recognized by plasma proteins such as CRP and natural IgM Ab. In various clinical settings 
and in animal models of ischemia and reperfusion, it has been demonstrated that complement 
activation by CRP and natural IgM Ab are major mechanisms of IRI. 
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Scope of the thesis 
The scope of this thesis is to assess the roles of CRP-, IgM- and anti-Pc-IgM-mediated 
complement activation in tissue damage, in particular in IRI. The objective is to provide more 
insight into the relative contributions of these proteins in this process. Chapter 2 reports a 
study on the capability of rCRP to activate rat complement and to mediate IRI. It provides 
experimental evidence that rat CRP is indeed able to activate the rat complement system upon 
ligand binding. This indicated that rat models are appropriate for studying the role of CRP in 
IRI. Chapter 3 concerns a study in rats. It reports that, although rat CRP levels increase upon 
estrogen replacement, this does not result in complement activation because there is not in 
generation of CRP ligands in this model. Chapter 4 deals with the role of CRP, IgM and anti-
Pc IgM in relation to complement activation in a rat model of intestinal IRI. The effect of C1-
inhibitor (C1-Inh) on inflammatory mediators was also studied. The study demonstrated that 
CRP, IgM and complement are deposited in the intestine after IRI. Furthermore, C1-Inh either 
administered before or at the end of ischemia reduced complement activation, indicating that 
it may have therapeutic benefits. Chapter 5 deals with the question whether or not anti-Pc 
IgM, like CRP, is a cardiovascular risk marker. For this study, an immunoassay was 
developed for the quantitation of anti-Pc IgM. In healthy donors and in patients with skin 
tumors undergoing isolated limb perfusion with tumor necrosis factor alpha, the relation 
between levels of anti-Pc IgM and CRP was investigated. The results suggest that anti-Pc IgM 
and CRP constitute two independent mechanisms involved in the elimination of injured cells. 
Chapter 6 is devoted to the relationship between IgM binding to apoptotic cells and infarct 
size in patients with AMI. The findings suggest that anti-Pc IgM levels may modify 
inflammatory responses and infarct size in patients with AMI.  
 Based on the literature and our own findings we hypothesize that during tissue damage 
as seen in ischemia and reperfusion, neoepitopes are exposed in the membranes of damaged 
cells. One of these neoepitopes could be Pc, the head group of lysophosphatidylcholine 
exposed after flip-flop of the membrane, oxidation and hydrolysis of the phospholipids by 
phospholipases A2. CRP and IgM may bind to Pc, and this binding may be followed by 
complement activation via the classical pathway. Because damaged tissue lacks regulatory 
molecules that in normal tissues prevent excessive complement activation, complement 
proteins may attack reversibly injured cells, which then become irreversibly damaged. 
Furthermore, we propose that the relative contribution of these proteins to complement 
activation after ischemia reperfusion varies between species, depending on their baseline 
values. For instance, in animals with high CRP levels and low IgM, as in rats, CRP will be the 
dominant activator of complement following IRI.  
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CHAPTER 2 
Rat C-reactive protein activates the autologous 
complement system
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Given current controvøsies regarding anti- and pro-inflammatory effects of estrogen, thae is a
need to explore relationships between gonadal hormones and inflammation using appropriate animal
models. It has been proposed that rats are not appropriate for such research since, contrary to the effect
of estrogen in humans, earlier animal studies had reported that estrogen downregulates serum C-reac-
tive protein (rCRP) levels in the rat. With these considerations in mind, we re-examined the effects of
estrogen withdrawal and replacement on CRP expression and complement activation in the rat. F-344
rats und8went bilateral ovariectomy or sham surg8y at 9-10 months of age. Four months lata, ovariec-
tomized rats were treated with traditional high-dose 1 7â-estradiol (Hi-E2) capsules, lowø-dose (Lo-E2) 1
7â-estradiol capsules, or placebo capsules for 7 days prior to sacrifice. Levels of plasma rat C-reactive
protein (rCRP) were significantly lower in ovariectomized vs. sham-operated animals (415.5 ± 10.6
vs. 626.6 ± 23.0 mg/L, p < 0.001). Estrogen replacement significantly raised rCRP levels in ovañec-
tomized animals (690.0 ± 28.0 mg/L in Lo-E2 and 735.5 ± 35.8 mg/L in Hi-E2, respectively, p <
0.001). Plasma rCRP levels correlated significantly with both hepatic rCRP (r = 0.79, p < 0.001)
and serum estradiol (r = 0.70, p < 0.001) levels. Howeva, no significant differences wae observed in
indices of complement activation (C4b/c) or CRP-complement complex genwation (rCRP-C3
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complex). In the mature female rat, ovariectomy reduces and estrogen replacement raises rCRP. Effects of
estrogen on plasma rCRP induction are mediated, at least in part, through hepatic mechanisms and
do not appear to require or be associated with complement activation.
Keywords Estrogen, Hormone replacement therapy, C-reactive protein, Complement
activation, Inflammation
INTRODUCTION
Cardiovascular disease (CVD) remains a leading cause of death in older
women (1). Post-menopausal declines in estrogens have been associated
with increased production of pro-inflammatory cytokines (2–5). In view of
mounting evidence that inflammation may play a critical role in the patho-
genesis of atherosclerosis, it has been proposed that declines in estrogen
could raise the risk of CVD in this population. C-reactive protein (CRP) is
an inflammatory marker and a strong predictor of cardiovascular events in
postmenopausal women (6,7). Based on these considerations, hormone
replacement therapy (HRT) with estrogen should exert anti-inflammatory
effects, yet in most human trials HRT increases CRP levels (8–11). It
remains to be seen whether estrogen-mediated elevations in CRP levels may
have contributed to the failure of recent randomized trials (12,13) to dem-
onstrate a cardiovascular benefit for HRT.
There is a need for animal studies to explore the relationship between
estrogen and CRP, since the mechanisms by which HRT induces CRP
remain unknown. It has been proposed that rats are not appropriate for
such research since estrogen downregulated serum CRP levels in earlier rat
studies (14,15). As an acute response reactant, one of the important host
defense functions of human CRP (hCRP) is to induce a self-sustaining
inflammatory process through complement activation (16). Although, it
had been suggested that rat CRP may be unable to activate complement
pathways, Diaz et al. have recently demonstrated the capacity of rat CRP
(rCRP) to activate the rat complement system in a manner similar to that of
hCRP (17). With the prior considerations in mind, we undertook a study to
re-examine the effects of estrogen withdrawal and replacement on CRP
expression, as well as complement activation, in the rat.
METHODS
Animal Model
Single colony 240 - 270g female Fisher-344 rats (Harlan Sprague-Dawley)
underwent bilateral ovariectomy (OVx) or sham surgery at 9-10 months of
age and were maintained in a pathogen-free colony. Four months after
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surgery, traditional silastic capsules (Dow Corning; #508-006) containing
100% (about 8 mg per capsule) 17ȕ-estradiol (Hi-E2, Sigma Chem.) were
implanted subcutaneously in the dorsal neck for 7 days (18). In other OVx
animals, a 1:4 mixture of 17ȕ-estradiol and Cholesterol (Lo-E2)(19) or
100% cholesterol (placebo, Aldrich Chemical Co.) were implanted. The
identical animal protocol was repeated in two separate experiments to
confirm the findings (n = 5 and n = 6 per treatment group in each of two
experiments). Rats were sacrificed following the onset of deep anesthesia
using i.p. administration of ketamine (40-60 mg/kg) and xylazine (3-5 mg/kg).
Blood samples were collected, kept on ice, and then processed within 3 hr
by centrifugation in 1,100 RCF at 4°C for 10 min. Serum or plasma was ali-
quoted and frozen at í80°C until analysis. All animal care was conducted
according to NIH guidelines and all protocols were approved by the Animal
Care Committee of the University of Connecticut Health Center.
Serum Estradiol Assay
Estradiol was measured using a 3r d Generation Estradiol RIA kit (Diagnostic
Systems Laboratories, Webster, TX, USA) following manufacturer’s instructions.
Protein Analysis
Total protein was measured in sera or hepatic homogenates using a BCA
protein assay kit (Pierce Chem.) following manufacturer’s instructions.
Plasma Rat CRP (rCRP) Analysis
Levels of rCRP were determined by ELISA (17) with a sensitivity of 0.01
mg/ L. The ELISA was performed with a polyclonal rabbit antibody raised
against purified plasma-derived rCRP. This antibody does not recognize
proteins in rCRP-depleted rat sera and hence is specific.
Hepatic rCRP
Liver tissues were collected, rinsed with ice-cold phosphate buffered
saline, pH 7.4 (PBS) x2, and snap frozen at í80°C. Frozen liver tissues were
cut to (50 mg per piece and were homogenized in cell-lysis buffer (Cell
Signalling Technology) supplemented with protease inhibitor cocktail-I
(Calbiochem). Cellular protein was extracted with slow agitation at 4°C for
1 hr and was then centrifuged at 13,000 rpm at 4°C for 20 min. Superna-
tants were collected and stored at –80°C for rCRP ELISA, as previously
described. An aliquot from each sample was taken for protein analysis used
to normalize the final rCRP value.
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Activated C4 (C4b/c) and rCRP-C3 Complexes
Plasma C4b/c was measured by ELISA as described previously (20).
Briefly, the IgG fraction of sheep antiserum against human C4, that crossreacts
with rat C4, was used as both a capture, as well as a detection, antibody.
Results were expressed as the percentage of the maximal amount of activated
C4 generated in rat serum by incubation with purified C1s (Calbiochem).
Because the assay does not discriminate between C4b, C4bi, or C4c, the activation
product detected was referred to as C4b/c. The ELISA for rCRP-C3 complex
quantifies the binding of rCRP to activated C3 (C3b and C3bi) as described by
Diaz et al. (17).
Statistics
One-way ANOVA with post hoc tests was used to determine the significance
of differences in multiple comparisons. Pearson correlation was used for
the relationship of serum rCRP with hepatic rCRP and estrogen. Analyses
were performed using SPSS version 11.0. A value of p < 0.05 was considered
significant.
RESULTS
Effects of Estrogen Deficiency and Replacement on Plasma
rCRP Levels
Four months after performing a bilateral OVx in these middle-aged
rats, plasma rCRP levels were significantly lower in OVx rats when compared
to age-matched sham-operated animals (Fig. 1, 415.5 ± 10.6 vs. 626.6 ± 23.0
mg/ L, p < 0.001). Providing E2 replacement to OVx rats significantly
increased rCRP levels to 690.0 ± 28.0 mg/ L in Lo-E2 group (p < 0.001 vs.
placebo-treated OVx animals) and to 735.5 ± 35.8 mg/ L in Hi-E2 group
(p < 0.001 vs. placebo-treated OVx animals). Ovariectomy resulted in only a
small decrease in serum total protein (placebo-treated OVx animals vs.
sham: 46.46 ± 2.13 vs. 51.45 ± 4.92 mg/ml, NS). However, as seen with
plasma rCRP, E2 replacement induced total protein production in a dose-
dependent pattern (57.14 ± 11.49 mg/ml in Lo-E2 group, NS vs. sham;
66.03 ± 14.02 mg/ml in Hi-E2 group, p < 0.05 vs. sham, respectively).
Relationships of Peripheral rCRP Levels to Hepatic rCRP and Serum
Estradiol
Although CRP synthesis takes place primarily in the liver, CRP can also
be expressed in the atherosclerotic arterial wall (21). Because it had been
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Sham OVx+placebo OVx+Lo-E2 OVx+Hi-E2
FIGURE 1 Plasma rCRP levels were significantly lower in ovariectomized vs. sham-operated animals
(415.5 ± 10.6 vs. 626.6 ± 23.0 mg/ L, n = 11 in OVx+Placebo and n = 10 in sham, *p < 0.001). Estrogen
replacement in ovariectomized significantly raised rCRP levels vs. ovariectomized receiving placebo
(690.0 ± 28.0 mg/ L in Lo-E2 and 735.5 ± 35.8 mg/ L in Hi-E2, respectively, n = 11, ‡p < 0.001).
proposed that increases in CRP levels following oral HRT merely reflects a
first-pass hepatic effect (22), we examined the expression of rCRP in
hepatic homogenates and its relationship to plasma rCRP (Fig. 2A). Our
data demonstrated that the plasma rCRP levels are significantly correlated
with both hepatic rCRP (r = 0.79, p < 0.001; Fig. 2A) and also serum estradiol
(r = 0.70, p < 0.001; Fig. 2B).
Complement Activation in Relation to Plasma rCRP
To determine the inflammatory consequences and biological significance
of E2-mediated rCRP elevation, we examined complement activation by measuring
C4b/ c levels, and also by detecting the binding of rCRP to activated C3 (C3b and
C3bi), which then generates rCRP-complement complexes (detectable as rCRP-
C3 complex). There were no differences among any of the treatment groups (Table
1). In fact, levels of C4b/ c and rCRP-C3 complex were essentially unchanged in
animals following OVx with or without E2-replacement. These results indicate
that E2-mediated rCRP elevation was not associated with evidence of enhanced
complement activation or the generation of rCRPcomplement complexes.
Furthermore, neither C4b/ c nor rCRP-C3 complex levels correlated with plasma
rCRP or serum estradiol levels (data not shown).
1000
400
200
800
600
0
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FIGURE 2 The correlation of plasma rCRP with hepatic rCRP and serum estradiol. (A) The levels of
plasma rCRP and hepatic rCRP were significantly correlated (n = 31, r = 0.79, p < 0.001). Hepatic rCRP
is expressed as mcg of CRP per mg of homogenate protein; (B) Plasma rCRP was also significantly correlated
with serum estradiol levels (n = 27, r = 0.70, p < 0.001).
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TABLE 1 Levels of plasma C4b/ c and rCRP-C3 complex
Sham OVx+Placebo OVx+Lo-E2 OVx+Hi-E2
C4b/ c, %NRA 13.52 ± 0.90 14.07 ± 0.93 13.11 ± 2.48 10.19 ± 2.44
P value — .996* .980‡ .401‡
95% confidence interval — (í5.886.98) (í7.575.65) (í10.492.73)
rCRP-C3 complex, U/ ml 0.98 ± 0.05 1.08 ± 0.28 1.04 ± 0.06 0.93 ± 0.17
P value — .972* 998‡ .923‡
95% confidence interval — (í.55.75) (í.69.61) (í.83.53)
C4b/ c levels represent complement activation and are expressed as % of normal rat aged (% NRA),
which represents 100% conversion of C4 to C4b/ c (n = 10 for sham and placebo, n = 9 for Lo-E2 and
Hi-E2). rCRP-C3 complexes quantify the binding of rCRP to activated C3 (n = 6 for each group, except
for n = 5 in Hi-E2). Data are presented as mean ± SEM. The missing values were due to inadequate fro-
zen blood specimens in some animals. There is no significance among groups by One-way ANO VA with
post hoc test (* P vs. sham, ‡P vs. OVx+Placebo).
DISCUSSION
Our study provides the first evidence that, as in humans, 17ȕ-estradiol
(E2) replacement increases plasma CRP levels in rats. Our observations are
in sharp contrast to previous reports (14,15) which showed that the subcu-
taneous injection of E2 resulted in decreased serum rCRP concentrations
in ovariectomized rats. Although E2 levels were not reported in these studies,
the administered doses (1 mg/kg) were most certainly in the pharmacological
range (14,15). The silastic capsules used in our study have been shown to
release less than 1 ȝg E2 every 24 hr (23). Thus, subcutaneous injections of 1
mg/kg E2 (14,15) to an adult rat would have delivered a dose of E2 nearly
400 times higher when compared to the doses used in our study. The effects of
such extremely high dose E2 on decreasing serum rCRP levels may have
been post-translational since it was also reported that hepatic rCRP mRNA
levels were unchanged in these animals (15).
Although CRP has been considered to be a sensitive, yet non-specific
inflammatory marker, our data indicates that E2-mediated increases in CRP
levels do not appear to be associated with evidence of enhanced comple-
ment activation. Most earlier studies have primarily focused on the impact
of HRT on those pro-inflammatory cytokines (e.g., IL-6) which may mediate
CRP production. In contrast, our study examined the important cascade of
complement activation in order to evaluate the biological consequences of
E2-mediated increases in CRP production. Activation of the complement
system via the classical pathway is one of the rigorously defined pathogenic
properties of human CRP (hCRP) which might contribute to an active role
of CRP in atherogenesis (24,25). However, it had been reported that rat
CRP is unable to activate complement (26,27). Given the fact that important
biological functions of proteins are probably conserved among species
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(25), Hack’s group has recently re-evaluated this issue, using various
ligands, and tested the capacity of rCRP to activate complement. They have
demonstrated that rat CRP, similarly to hCRP, can activate autologous com-
plement upon ligand-binding (17). In fact, CRP is only able to activate com-
plement when it is aggregated to form dimers or trimers. CRP aggregation
can be achieved when it is bound to appropriate ligands, such as phospho-
choline (20,24,28). Gershov et al. (29) have reported that CRP is able to
bind to apoptotic cells, but not to normal cell membranes. Aggregation of
CRP upon ligand-binding and the subsequent complement activation gen-
erate CRP-complement complexes. Lagrand et al. (30) have reported that
CRP colocalized with the deposits of activated C4 and C3 fragments in inf-
arcted human myocardium. Interestingly, Griselli et al. (27) have shown
that the administration of hCRP to rats after ligation of the coronary artery
enhanced infarct size by 40%. However, in vivo complement depletion com-
pletely abrogated this effect and markedly reduced infarct size. These find-
ings suggest that complement activation by CRP represents an important
mechanism of CRP-mediated tissue damage.
We observed no difference in the levels of generated C4b/ c and rCRP-C3
complexes among sham, OVx/ placebo, OVx/ Lo-E2, and OVx/ Hi-E2 groups.
Our results do not provide any evidence of enhanced complement activation
following ovariectomy or E2 replacement. An alternative explanation arises
from the fact that complement activation by rCRP requires ligand-binding
and that rats have unusually high rCRP concentrations under basal condi-
tions; e.g., approximately 300-500 mg/ L (17). With these considerations in
mind, it is possible that although rCRP increases upon E2 replacement, this
does not result in enhanced complement activation, since levels of appropriate
ligands for rCRP do not rise simultaneously and, thus, become limiting. These
observations also support our previous reports that C4b/ c and CRP-C3 complex
are specific markers for complement activation by human or rat CRP
(28,30), and that elevated CRP levels in the absence of appropriate ligands
are not associated with enhanced complement activation (28,30). Thus, it is
possible that while estrogen-mediated increases in CRP levels may enhance the
risk of inflammation, additional conditions (e.g., elevations in levels of CRP
ligands) must also be present for complement activation and a full
inflammatory response to take place. Our observations indicating no evidence
of enhanced complement activation in relation to elevated CRP could help
explain several observations from recent clinical trials. In the WHI-OS (8),
CRP was an independent predictor of cardiovascular risk for both users and
nonusers of hormone therapy. However, use or nonuse of ERT had less
importance as a predictor of cardiovascular risk than did CRP levels. More-
over, hormone therapy assignment did not significantly change stratified
odds ratios based on CRP levels. Thus, the E2-mediated increase in CRP
could not be totally equated with an increased cardiovascular risk.
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Although most human studies of oral HRT indicate induction of CRP
production, there are considerable controversies regarding both the direc-
tion and the magnitude of the effects of HRT on proinflammatory cytokines.
Studies evaluating the effect of HRT on circulating IL-6 levels have yielded
highly inconsistent results, suggesting that HRT increases (31), decreases
(8,32,33), or does not change IL-6 levels (8,34,35). These discrepancies high-
light the complex nature of the relationship between estrogen and inflammation.
Many types of inflammatory cells are responsive to estrogen (36). Although IL-
6 appears to be the major stimulant for hepatic CRP production, mechanisms
independent of IL-6 have also been described (37). Other inflammation-
associated cytokines, including IL-1â, TNF-á, IFN-ã, and TGF-â may exert additive,
inhibitory or synergistic effects on hepatic CRP expression (38). Bruun et al.
(39) have reported results of animal studies indicating that ovariectomy
significantly increased IL-6 and IL-8 gene expression in rodent adipose tissue,
with no apparent effects on TNF-á gene or protein level. Low dose E2
replacement administered at the time of ovariectomy and continued for 5
months prevented these increases. However, no direct effects of E2 on these
three adipose tissue-derived cytokines were observed in adipose tissue cultures
following 24-hr incubation. These findings suggest that the effect of E2 on
these cytokines may be more long-term, or that the in vivo effects of E2 on
cytokines are mediated indirectly through one or more mediators. It has become
apparent that the biological effects of E2 on inflammation are highly complex and
clearly not well understood.
Stork et al. (40) reported that combination therapy using 17â-estradiol
daily plus standard dose of progestin cyclically had a neutral effect on CRP
levels and favorable effects on cell adhesion molecules, suggesting that the
type of E2 included in the HRT regimen affects the inflammatory response.
Preliminary findings from recent studies suggested that transdermal E2,
unlike oral conjugated E2, does not affect CRP adversely (22,34,41,42).
Therefore, it has been speculated that the HRT-mediated increase in CRP
could be due to a hepatic first-pass effect on CRP production, rather than a
true systemic inflammatory reaction. However, we found that E2 also ele-
vates rCRP levels when administered subcutaneously, raising both hepatic
and peripheral rCRP levels. Thus, hepatic activation does probably contribute
to the increased CRP production following E2 replacement, irrespective of
the route of administration. Furthermore, based on our observation of the
dose-dependent patterns of rCRP and total serum protein changes in relation
to serum E2 levels, we speculate that the increases in levels of rCRP and total
protein may both reflect a systemic anabolic effect of estradiol through
stimulation of hepatic synthesis. In fact, E2 has been shown to regulate the
hepatic production of abundant serum proteins, including albumin (43)
and ceruloplasmin (44). In contrast, proinflammatory cytokines, principally IL-
6, inhibit the hepatic synthesis of albumin and transferrin in
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inflammatory responses (45). Of interest, several recent studies (46–48)
have reported that lower oral dose E2 therapy did not raise CRP levels,
while conventional doses did. Our data did not show significant differences
in rCRP levels between Lo-E2 (25% of estradiol capsule) and Hi-E2 (100%
of estradiol capsule) groups. In our study, serum estradiol levels in Lo-E2
rats were still above the proestrus range, yet they were significantly lower
than the levels in Hi-E2 animals (Fig. 2B). Nevertheless, we were unable to
assess the effects of even lower doses of E2 on inflammation in this rat
model.
In conclusion, we found that contrary to earlier reports, ovariectomy
significantly reduced and E2 replacement significantly increased plasma
rCRP in middle-aged rats. Levels of peripheral rCRP correlated with serum
E2 and hepatic rCRP. However, the E2-mediated elevation of rCRP was not
associated with enhanced complement activation or rCRP-complement
complex formation. Our data support the notion that the E2-mediated
increases in CRP may not represent an upregulation of the inflammatory
response. Further studies examining yet lower doses of E2 on CRP produc-
tion and related vascular inflammatory changes are needed.
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Abstract  
The role of C-reactive protein (CRP), natural immunoglobulin M (IgM), and natural IgM 
against phosphorylcholine (anti-Pc IgM) was investigated in relation to complement 
activation, in a rat model of intestinal ischemia and reperfusion (II/R). The effect of C1-
esterase inhibitor (C1-Inh) on this complement activation along with other inflammatory 
mediators was also studied. Rats were subjected to 1 h of superior mesenteric artery (SMA) 
occlusion and 3 h of reperfusion. Intravenous administration of vehicle (human albumin) or 
C1-Inh (200 U/kg) was performed before (n=8) or after ischemia (n=8). II/R increased levels 
of C4b/c, CRP, IgM, anti-Pc IgM and myeloperoxidase activity in the intestinal homogenates 
and induced vascular leakage. A good correlation was observed in the intestinal homogenates 
between C4b/c and CRP levels. Clear depositions of C3, CRP and IgM in intestinal tissue 
were demonstrated after II/R. In the tissue, a strong correlation of both CRP and IgM with 
complement was observed. C1-Inh prior to ischemia reduced complement activation response 
following II/R, as reflected by decreased levels of C4b/c in conjunction with reduced anti-Pc 
IgM, in the intestinal homogenates. C1-Inh also diminished the leakage of albumin when 
administrated prior to ischemia. C1-Inh post ischemia reduced C4b/c levels in the 
homogenates and myeloperoxidase activity. CRP and IgM depositions correlated well with 
local complement activation, suggesting a role for these molecules in complement activation. 
Furthermore, C1-Inh potentially inhibited II/R injury either administered prior to or after 
ischemia, by attenuating complement activation induced by CRP and/or natural antibodies.  
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Introduction 
Induction of ischemia in organs leads to changes in the endothelial cells of the vasculature. 
These changes include ATP depletion and altered production of bioactive agents, leading to 
apoptosis and necrosis and finally in loss of organ function. Restoration of blood supply 
(reperfusion) exacerbates these changes and aggravates endothelial cell damage, at the same 
time inducing an inflammatory response [1]. II/R injury is associated with a high morbidity 
and mortality [2]. Additional damage to the injured intestinal tissue is attributed to the 
activation of the complement system [3-5]. 
 Two activators of the complement classical pathway, i.e. CRP and natural IgM, have 
been described in relation with ischemia reperfusion (I/R). CRP, the classical acute phase 
protein in humans, co-localised with activated complement on human infarcted myocardium 
[6]. In addition, intraperitoneal injection of human CRP increased infarction size in an 
experimental myocardial infarction model in a complement-dependent fashion in rats [7], 
which furthermore demonstrated the involvement of CRP in complement-mediated tissue 
injury following I/R. This co-localisation of CRP and complement may result from cell 
membranes harbouring binding sites for CRP which can bind to phosphorylcholine (Pc) 
exposed on the injured membranes, after which the classical pathway is activated [8,9]. In 
mice, it has been shown that natural IgM participates in the activation of the classical pathway 
upon II/R [10-12]. A specific self-reactive IgM antibody, able to initiate intestinal and hind 
limb reperfusion injury in murine models of I/R, was identified [13, 14]. In the infarcted 
human myocardium IgM colocalized with complement [15]. Krijnen et al., showed that IgM 
also co-localised with CRP, strongly suggesting that both proteins share a similar specificity, 
possibly Pc. Others have shown that natural IgM directed against Pc (anti-Pc IgM) binds to 
damaged cells and plays a role in complement activation [16, 17].  
 In rat models of II/R, several inhibitors of complement have been evaluated. 
Administration of the inhibitor prior to ischemia [3, 18] or prior to reperfusion [19, 20] both 
resulted in a reduction in intestinal injury. C1-Inh is a serine proteinase inhibitor of both the 
classical and mannan-binding lectin pathway [21]. Administration of human C1-Inh prior to 
reperfusion attenuated II/R injury in mice [22]. These studies indicate that inhibition of 
complement activation may be effective in the reduction of I/R induced intestinal injury. 
 The aim of this study was to investigate the contribution of both CRP and natural IgM 
in complement activation in an II/R model in the rat, as well as  the potential inhibition of this 
complement activation, using human C1-Inh administration prior to or after ischemia. 
Materials and Methods 
Animals 
Male Wistar rats (Charles River, Broekman Institute B.V., Someren, The Netherlands) 
weighing 250 to 300 g, were allowed to adjust for one week and were subjected to a regimen 
of 12:12 h /day-night cycle at constant temperature (22ºC). Food and water were supplied ad
libitum. Twelve hours before the experiment, animals were fasted with free access to water. 
All animals were handled in accordance with the guidelines prescribed by the Dutch 
legislation and the International Guidelines on protection, care and handling of laboratory 
animals. The Animal Ethics Committee of the Academic Medical Center has approved all 
experimental procedures.
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Intestinal model of ischemia and reperfusion  
Animals were weighed and pre-medicated with 4% isoflurane (Florene®, Abbott Laboratories 
Ltd. Queensborough, Kent, UK) and temgesic (0.033 ml/100 gram bodyweight) (Schering-
Plough, Amsterdam, The Netherlands). After endotracheal intubation, the rats were ventilated 
(Zoovent ventilator, Instruvet, Amerongen, The Netherlands) by inhalation of air: 02 (1:1) and 
2% isoflurane. Anaesthesia was maintained during the entire experiment. The mean arterial 
blood pressure was measured via a canula in the carotid artery and was maintained between 
80 and 110 mmHg during the entire experiment. Fluid infusion (3 ml per hour with 0.9% 
NaCl, (Baxter B.V., Utrecht, The Netherlands) was administered via the carotid artery. Body 
temperature was kept at 37°C and pCO2 at approximately 35 mmHg. 
 II/R was induced as previously described [23]. Briefly, using a midline laparotomy, 
the SMA was clamped with a non-traumatic vascular clip. Clamping was confirmed by 
immediate blanching of the small intestine and cecum, and lasted for 1 h. Removal of the 
vascular clip restored blood flow, which was evidenced by the reappearance of the original 
colour of the intestine. Reperfusion was carried out for 3 h. Sham animals underwent the same 
surgical intervention except for clamping of the SMA. 
  Blood samples were collected via the portal vein (1 mL) in siliconized vacutainer 
tubes at a final concentration of 10 mM EDTA (BD microtainer K2 EDTA tubes, Franklin 
Lakes, U.S.A), 5 min before ischemia and 10, 60 and 180 min during reperfusion. Plasma was 
obtained by centrifugation at 1,200 x g for 10 min at 4°C and aliquots were stored at –80°C. 
Blood loss, due to blood sampling, was corrected by administration of 1 mL of eloHaes 
(Fresenius Kabi Nederland B.V.,‘s Hertogenbosch, The Netherlands). After 3 h of reperfusion 
the rats were sacrificed by bleeding followed by cardiac-perfusion with 30 mL of 0.01 M 
phosphate-buffered saline, pH 7.4 (PBS; Fresenius Kabi Nederland) to clear the organs from 
blood. 
 A segment of the small intestine was collected 10 cm proximal from the cecum. After 
weighing the intestinal segments, the lumen was flushed with 30 mL of PBS. The intestine 
was divided into four sections, which each in turn were divided into four parts. From each 
section one part was collected (4 parts in total from 4 different sections) and either frozen in 
liquid nitrogen and stored at –80°C or fixed in 4% (w/v) formaldehyde for further studies. The 
distal side was marked with a suture. 
Blood gas measurement in arterial blood 
The values of pH, PCO2, PO2, base excess and HCO3 were assessed in peripheral arterial blood, 
collected at the end of the experiment, using the ABL analyzer (Radiometer, Zoetermeer, The 
Netherlands). 
Parameters of intestinal injury  
Intestinal injury was assessed using the classification of Park-Chiu [24]. Four different 
sections of the formaldehyde fixed jejunum from each animal were embedded together in 
paraffin. Each section was cut at three different levels. 4 ȝm sections were stained with 
haematoxylin and eosin. A blinded observer assessed the slides microscopically according to 
a semi-quantitative scorings methodology. Briefly, the scores used were 0: normal mucosa; 1: 
subepithelial space at villus tips; 2: extension of subepithelial space with moderate lifting; 3: 
massive lifting down sides the villi, some denuded tips; 4: denuded villi; dilated capillaries; 5: 
disintegration of the lamina propia; 6: crypt layer injury; 7: transmucosal infarction; and 8: 
transmural infarction. 
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Myeloperoxidase activity 
Myeloperoxidase (MPO) activity, an index of neutrophil infiltration, was measured in the 
intestine as described by Krawisz et al. [25] with minor modifications. Briefly, 30-50 mg of 
intestinal tissue was homogenised (Heidolph, Diax 900) in 5 mM sodium phosphate buffer, 
pH 6.0. After a sample was taken from the homogenate for protein content determination 
(Pierce Biotechnology, Inc Rockford IL, USA), it was centrifuged for 10 min at 12,000 x g at 
4ºC. The pellet was homogenized in 0.5% hexadecyltrimethyl ammonium bromide (Sigma-
Aldrich Chemicals BV, Zwijndrecht, The Netherlands) and 10 mM EDTA in 50 mM sodium 
phosphate buffer, pH 6.0. Homogenates were freeze-thawed three times, pottered 10 times 
(Bellco 20, RW 20.n IKA Labortechnik), sonicated for 10 sec and centrifuged at 12,000 x g at 
4ºC for 10 min. The supernatants were collected and assayed for MPO activity by addition of 
0.167 mg/ml o-dianisidine dihydrochloride (Sigma-Aldrich Chemicals) and 0.001% H2O2
(Sigma-Aldrich Chemicals) in 50 mM sodium phosphate buffer, pH 6.0. The change in 
absorbance was measured spectrophotometrically (Victor2, Wallec 1420) at 450 nm during 10 
min at 37ºC. One Unit is defined as the amount of enzyme necessary to produce a change in 
absorbance of 1.0 per min. The MPO activity was expressed as units per mg protein.  
C1 esterase inhibitor and albumin administration 
Human C1-Inh (200 U/kg bodyweight) (Cetor, Sanquin Research, Amsterdam, The 
Netherlands) was administered i.v. via the penile vein either 5 min before ischemia (C1-Inh+ 
II/R) or 5 min before reperfusion (II/R+ C1Inh), (n=8 per group). Human albumin (Alb) 
(Cealb, Sanquin Research), administrated in a similar fashion and in an equal protein load as 
C1-Inh, served as a reference for the intervention with C1-Inh (Alb+ II/R and II/R+ Alb, 
respectively, (n=8 per group). Furthermore, four groups (n=6 rats per group) were included to 
investigate the effects of C1-Inh or Alb in the anaesthetised rats (sham groups). One hour of 
ischemia was replaced by one hour of anaesthesia. In total, four randomised groups were used 
to investigate the effects of C1-Inh administration prior to ischemia. Four additional 
randomised groups were used to investigate the effects of C1-Inh after ischemia. 
Preparation of the intestinal homogenates 
Intestinal tissue (1 part of the frozen sections, as described above) was crushed upon freezing 
in liquid nitrogen. All powders were stored at –80°C until use. All following procedures were 
performed at 4°C. Pulverised tissue was resuspended in veronal buffered saline (0.1%, w/v, 
Tween 20, 0.5 M NaCl, 10 mM EDTA, pH 7.4, final concentrations) and incubated for 4 h. 
This suspension was centrifuged (12,000 x g for 20 min). The supernatant was used for 
further analysis. 
Determination of total protein and albumin concentration 
Protein content in both plasma and in the intestinal homogenates was measured using the 
BCA protein assay (Pierce Biotechnology, Inc Rockford IL, USA). Albumin was quantified in 
the intestinal homogenates using the rat albumin ELISA quantitation kit (Bethyl laboratories, 
INC, West FM 1097 Montgomery, TX, USA).  
ELISA for C4b/c and CRP quantification 
The levels of activated C4 were used as parameter for complement activation. They were 
measured in plasma and in intestinal homogenates as described previously [26]. As the assay 
does not discriminate between C4b, C4bi or C4c, the activation product detected was referred 
to as C4b/c. Results were expressed as percentage (%) of C4b/c in the samples compared to 
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that of aged normal rat plasma (NRA). NRA was used as a house standard in this ELISA. Rat 
CRP was quantified by ELISA as previously described [27]. Results were expressed as 
ȝg/mL. The C4b/c and CRP levels measured were adjusted to the total protein concentration 
in each sample.  
ELISA for C1-Inh, IgM and anti-Pc IgM quantification
The levels of human C1-Inh, natural rat IgM and anti-Pc IgM were measured both in plasma 
and in the intestinal homogenates. C1-Inh was detected as described before [26, 28]. Results 
were quantified by comparison with a standard consisting of normal rat plasma supplemented 
with 250μg/mL (equivalent to 1 U/ ml) of human C1-Inh.  
 IgM and anti-Pc IgM were quantified as follows. Maxisorp plates (Nunc Band 
Products, Denmark) were coated with goat anti-rat IgM (μ chain specific), (SouthernBiotech, 
Inc, Birmingham, USA) at 1 μg/mL in 0.1 M carbonate/bicarbonate buffer, pH 9.6 overnight 
at 4°C for the quantification of IgM. Instead of goat anti-rat IgM, the plates were coated with 
Pc-BSA (Biosearch Technologies, Inc. 81 Digital Drive Novato CA, USA) for anti-Pc IgM 
quantification. Final volume in the wells was 100 µl, unless stated otherwise. After washing 
the plates twice with PBS, residual binding sites were blocked with BSA (Intergen company, 
Purchase, NY , USA) at 2% (w/v) in PBS (200 μl/well) for 1 h at room temperature. The 
plates were then washed with PBS/0.02% (w/v) Tween 20. Samples to be tested were diluted 
in veronal buffered saline containing 10 mM EDTA (to prevent calcium-dependent CRP 
binding to Pc), 0.1% (w/v), BSA, 0.1% (w/v) Tween 20, pH 7.4, (assay buffer). Bound rat 
IgM was detected by goat anti-rat IgM labelled with HRP (Bethyl laboratories, INC, West 
FM, and Montgomery, USA) diluted in assay buffer. Finally, plates were washed and 
peroxidase activity was visualized by incubation with 3,3’, 5,5’,-tetra-methyl-benzidine, 100 
µg/ml in 0.11 M sodium acetate, pH 5.5, containing 0.003% (v/v) H202. The reaction was 
stopped after 10 min by addition of 2 M H2S04, and the absorbance at 450 nm was measured 
with a Titertek plate reader. C1-Inh, IgM and anti-Pc IgM levels were also adjusted to the 
total protein concentration in each sample. 
Immunohistochemistry 
Depositions of activated rat C3, CRP and IgM were assessed using frozen sections (4 μm 
thick) from the proximal and the distal part of the jejunum (two sections instead of the four 
combined for the homogenates). Rabbit polyclonal antibodies against rat C3 (gift from Dr. 
Daha M. R., Leiden University Medical Center, Leiden, The Netherlands) and CRP [27], 
followed by the polyclonal goat anti-rabbit immunoglobulins/HRP (DAKO Cytomation, 
Glostrup, Denmark) were used to detect C3 and CRP deposition. Deposition of rat IgM was 
examined with the goat anti-rat IgM labelled with HRP (Bethyl laboratories, INC, West FM, 
and Montgomery, USA). Irrelevant rabbit IgG and goat IgG were used as isotype controls. 3, 
3'-diaminobenzidine-tetrahydrochloride (Sigma, St Louis, Missouri, USA) at 0.5 mg per ml in 
PBS, pH 7.4, containing 0.01% (v/v) H2O2, was used as substrate. The slides were 
counterstained with haematoxylin for one min, dehydrated, cleared, and finally mounted. The 
extent of depositions was examined both in the mucosa and in the mucosal debris present in 
the lumen and was quantified using a video overlay system (QPRODIT 5.2, Leica) [29]. Each 
tissue slide was subdivided into five parts at magnification 250 times. For the mucosa, a photo 
of each part was taken and the total (cm2) and the positive area (cm2) for C3, CRP, and IgM 
was calculated and expressed as the percentage of deposition. Finally, the mean value of the 
percentage determined from the five parts was used for analysis. The percentage of the 
microscopic field positive for C3, IgM and CRP was also assessed for mucosal debris present 
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in the lumen of each slide. Two investigators judged and scored all slides without knowledge 
of the experimental groups. The final scores were obtained after consensus between the two 
investigators. No staining for C3, CRP or IgM was observed with irrelevant rabbit or goat 
polyclonal antibodies.   
Data analysis 
Data were expressed as mean ± SEM in text, tables, and figures except for the Park Chiu score 
for which median values were used. Statistical analysis was assessed by Kruskal Wallis / 
Mann-Whitney using Statistical package for the Social Sciences (SPSS 11.5, SPSS Inc, 
Chicago, Illinois, United States of America). Correlations between parameters were assessed 
by estimating Spearman’s rank correlation coefficient (Rs). Plasma parameters measured were 
evaluated by ANOVA for repeated measurements. p<0.05 is considered significantly 
different. 
Results 
All animals (n = 56) in the experiment were included. The average body weight of the animals 
was 280 ± 1.3 gram. The pH, PCO2, PO2, HCO3 and base excess in the arterial blood at the end 
of reperfusion were indicative of proper ventilation strategies during the entire experiment. 
After administration of C1-Inh, its plasma level was significantly increased, as expected. 
Differences between the ischemic or sham groups were not observed. In addition, plasma 
levels of C4b/c, CRP, IgM and anti-Pc IgM adjusted for total plasma protein concentration did 
not differ between the sham and II/R groups (data not shown).  
Intestinal injury and neutrophil sequestration 
As expected, intestinal injury following I/R was significantly increased compared to sham 
operated animals, as reflected histologically by complete disintegration of the lamina propia 
(5.0 vs. 0.5 in sham and II/R, respectively, p <0.05) Figure 1A). Increased levels of MPO 
activity were measured in homogenates from animals receiving albumin after 1 h of ischemia 
and 3 h of reperfusion compared to the sham operated animals (Figure 1B). Although 
inhibition of the classical and mannan binding lectin pathway of the complement system by 
C1-Inh did not show a significant reduction of morphological injury (Figure 1A), it reduced 
the MPO levels significantly when administered immediately before the reperfusion period 
(Figure 1B).  
Complement activation and CRP, IgM and anti-Pc IgM levels in the intestinal homogenates  
Complement activation following II/R, as measured by C4b/c levels, was significantly 
increased (Figure 2A). In association with complement activation, levels of CRP, IgM and 
anti-Pc IgM were also increased (Figure 2B-D). The increased levels of C4b/c after II/R injury 
were reduced after administration of C1-Inh either before or at the end of ischemia, although 
these did not reach the level of the sham group. C1-Inh administered before ischemia not only 
reduced complement activation but also significantly decreased the anti-Pc IgM level (Figure 
2D). However, no effect of C1-Inh on CRP and IgM levels was detected in the intestinal 
tissues after I/R (Figure 2 B-C). 
 To assess the relationship between CRP, IgM, anti-Pc IgM and their contribution to 
complement activation, the correlation of these parameters using Spearman‘s rank correlation 
test was analysed (Table 1). A good correlation between complement activation (C4b/c) and 
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increased CRP levels (Rs 0.769, p<0.01) was observed. C4b/c and IgM levels were not 
significantly correlated, nor were the C4b/c and anti-Pc IgM levels. There was correlation 
however between CRP versus IgM and CRP versus anti-Pc IgM.  
Vascular leakage 
II/R increased intestinal wet weight- versus bodyweight ratio (p<0.05). C1-Inh did not reduce 
the intestinal wet weight -versus bodyweight ratio. The effect of vascular permeability after 
I/R was evaluated by measurement of the albumin content in the intestinal homogenates. The 
groups with II/R had increased levels of albumin compared to these of the sham groups 
(p<0.05). A significant reduction was observed after C1-Inh administration prior to ischemia 
(data not shown).  
Deposition of complement, CRP and IgM in intestinal tissue after I/R. 
Immunohistochemical assessment of intestinal frozen sections was performed to confirm that 
the observed increase in complement activation, CRP and IgM in the intestinal homogenates, 
was a result of actual binding to the membrane and not due to vascular leakage. In the sham-
operated rats, no depositions of C3 (A), CRP (B), or IgM (C) were detected (Figure 3). C3 
depositions were observed on the intestinal mucosa, in the subepithelial space, as well as on 
(damaged) mucosal fragments within the lumen of the intestine after 1 h of ischemia and 3 h 
of reperfusion (D). CRP and IgM were also deposited upon II/R (E and F, respectively). The 
percentages of C3, CRP, and IgM depositions through out the mucosa and the lumen were 
significantly increased in the II/R groups compared to the sham groups (Table 2 A, B). 
 Macroscopic examination showed marked differences in appearance of the ischemic 
segments of the intestine after I/R, with more evidence of infarction, edema, and haemorrhage 
in the distal segments. It was associated with a significant increase in the areas of the mucosa 
in the distal part compared to the proximal parts of the intestines (90.7 cm2 ± 7.3 vs. 69.6 cm2
± 5.1). In order to see whether these macroscopic differences were related to increased 
exposition of binding sites for CRP and/or IgM and increased complement activation in the 
distal intestinal segments, the percentages of depositions for all proteins in the proximal 
versus the distal frozen sections were compared (Wilcoxon matched pairs test, results not 
shown). Indeed, both CRP and C3 depositions were significantly increased in the distal 
segments of the mucosa.  
 Administration of C1-Inh before reperfusion resulted in reduction of the percentage of 
C3 depositions in the lumen compared to the rats given albumin before reperfusion (73.1 ± 6.0 
vs. 48.5 ± 7.0, for II/R+ Alb and II/R+C1-Inh respectively). This reduction was however not 
significant (p 0.091). Other effects of C1-Inh on the depositions of C3, CRP, and IgM were 
not detected. 
Correlation between C3, CRP, and IgM depositions  
To study the relative contribution of CRP and IgM to complement activation, correlations 
were performed between percentages of C3, CRP and IgM deposition in the lumen and in the 
mucosa. Strong correlations were observed between the percentages of depositions of C3-
CRP, C3-IgM, and CRP-IgM in the distal part of the lumen and for C3-CRP and CRP-IgM in 
the proximal part of the lumen. No correlation between C3-IgM in the proximal part of the 
lumen was found (Table 3). There was no correlation between the percentages of depositions 
of CRP and IgM, and complement in the proximal part of the mucosa. In addition, a weaker 
correlation between C3-CRP and CRP-IgM was found in the distal part of the mucosa in 
comparison to the proximal part (Table 3).   
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Discussion  
A role of the complement system in I/R injury in various organs including the intestine is well 
documented. However, the exact mechanisms triggering complement activation in II/R, is not 
completely clear. In mice, a role of natural IgM antibodies herein has been postulated [10-12]. 
In humans, both IgM and CRP seem to play a role in complement activation after cardiac I/R 
injury [15]. In the present study, 1 h of intestinal ischemia followed by 3 h of reperfusion led 
to depositions of C3, CRP and IgM in intestinal tissue. This was associated with increased 
levels of complement, CRP, IgM, anti-Pc IgM in intestinal homogenates from rats subjected 
to II/R. C1-Inh administration either prior to or after ischemia inhibited the classical pathway 
of complement activation as observed in the homogenates. However, the decrease in 
complement deposition found upon C1-Inh treatment was not significant. Protective effects of 
C1-Inh decreasing vascular leakage and neutrophil infiltration in the ischemic intestinal tissue 
were also observed when it was administered before or after reperfusion respectively.  
 Endogenous CRP was found to localize in ischemic myocardium in a rat model of 
acute myocardial infarction [7]. The present study demonstrated that post ischemically 
reperfused intestinal tissue not only contained CRP but also IgM, implying that at least two 
different proteins may also be involved in II/R-induced complement activation. The 
correlation between CRP and C4b/c deposition was better than this between IgM and C4b/c 
levels in the homogenates. These results suggest that CRP is more important for complement 
activation in this model than IgM. However, in the mucosal debris in the lumen a good 
correlation between C3 and both CRP and IgM was observed (Rs 0.698 and Rs 0.637 
respectively). It is possible that in animals with low CRP and normal IgM levels (such as 
mice); IgM will be the dominant inducer of complement activation during I/R injury. In 
animals with high CRP levels and normal IgM levels such as the rat, both CRP and IgM are 
likely to be involved in complement activation.  
 The reason for the observed increase in depositions of complement activators in the 
distal part of the lumen compared to the proximal part is not clear. The increased binding of 
C3, CRP and IgM in the distal part of the intestine cannot be explained by collaterals, since 
shunting via collateral blood flow would have resulted in less tissue damage. Rinsing of the 
intestine after excision may be a more likely explanation, as this will result in an increase in 
luminal mucosal debris more distally. There seems to be a high degree of similarity between 
the correlations for the various components observed in the homogenates in comparison to the 
depositions found in the lumen of the intestine. Some difference in correlation coefficients 
between the homogenates and the depositions may be because the homogenates represent the 
mean of the combined lumen and mucosa (distal and proximal). Apparently, injured mucosa 
is able to bind complement activators that will be lost in the lumen. Less injured mucosa will 
remain attached. Consequently, less complement activators will bind to the intact mucosa.  
 Complement activation as measured in the intestinal homogenates was inhibited by 
C1-Inh administration either prior to or after ischemia. The levels of anti-Pc IgM in these 
homogenates were significantly reduced by C1-Inh administration prior to ischemia, in 
contrast to CRP and IgM levels. C1-Inh may prevent membrane changes owing to decreased 
insertion of the membrane attack complex in the membrane. A reduction in membrane 
changes leads to reduced exposure of Pc epitopes, resulting in reduced binding of anti Pc-
IgM. However, both anti-Pc IgM and CRP are able to bind to Pc in ischemic tissue as 
measured in the homogenates. CRP can apparently still bind to the exposed Pc, while anti-Pc  
 IgM shows reduced binding upon C1-Inh administration. The different effect of C1-
Inh on anti-Pc IgM and CRP binding to the ischemic intestinal tissue also suggests that anti-
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Pc IgM and CRP have different binding affinities for Pc. Recently, two types of membrane-
associated neoantigens for Pc were detected on apoptotic cells and on oxidized low density 
lipoprotein [30]. This suggests subtle variations in the exposure of specific Pc epitopes, which 
may reflect the stage of apoptotic cell death or the biological context of the tissue that 
expresses Pc as haptens. This could also be true for CRP and anti-Pc IgM binding to Pc 
epitopes in ischemic intestinal tissue. Another mechanism to explain the inhibitory effect of 
C1-Inh on the reduction of anti-Pc IgM levels could be that both molecules bind to the same 
structure on the damaged intestinal cell membranes. However, the binding of C1-Inh to Pc 
molecules has not been identified. Moreover, the exact antigen recognized by IgM antibodies 
has not been identified. It has been reported that another ligand than Pc is involved as well in 
the binding of natural IgM to ischemic cells such as a  protein of about 250 KDa presenting on 
the damaged intestinal tissue [13]. Analysis of this high molecular mass band yielded peptide 
sequences homologous to nonmuscle myosin heavy chain type II C. A synthetic peptide 
representing a conserved region of nonmuscle myosin heavy chain type II C significantly 
blocked intestinal reperfusion injury mediated by IgM in immune deficient mice [31]. It is 
known that IgM binding to ischemic skeletal muscle already starts at the onset of ischemia 
and proceeds during reperfusion [32]. Therefore, inhibition of IgM binding by C1-Inh could 
be an additional protective action of this drug.  
 C1-Inh reduces neutrophil influx as measured by MPO levels and vascular leakage. 
This protective action of C1-Inh has been reported and may be a direct effect of C1-Inh 
binding to selectins expressed on the ischemic endothelial cell membrane [33]. Hence, via this 
effect C1-Inh may prevent extravasation of neutrophils, resulting in reduced formation of pro-
inflammatory substances. However, an alternative mechanism to explain the effect of C1-Inh 
on neutrophil influxes may be the reduction of C5a formation, a potent anaphylatoxin, via a 
reduction in complement activation. C1-Inh (200 U/kg bodyweight) administered in a mouse 
model of 30 min of intestinal ischemia and 2 h of reperfusion resulted in beneficial effects on 
the mucosa [22]. In this study however, no beneficial effect on the mucosa was observed. A 
higher dose might have been more effective, since C4b/c activation was not completely 
reduced by C1-Inh. Another reason may be the severity of the intestinal damage induced upon 
1 h of ischemia and 3 h of reperfusion. The damage inflicted to the intestine may have been 
too severe and therefore less responsive to treatment.  
 In conclusion, the observed strong correlation of both CRP and IgM in relation to 
complement activation in intestinal ischemic tissue is suggestive that both compounds 
contribute to this activation process. C1-Inh inhibits complement activation when 
administered either prior to or after the ischemic period. C1-Inh potentially inhibits II/R 
induced injury either administered prior to or after ischemia.  
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Figure 1. Effect of C1-Inh on ischemia reperfusion induced mucosal injury and neutrophil 
infiltration (MPO) after ischemia and reperfusion. Rats were injected i.v. with Alb or C1-
Inh either prior (Alb+II/R; C1-Inh+II/R) to or after (II/R+Alb; II/R+C1-Inh) 1 h of ischemia. 
After 3 h of reperfusion, mucosal injury (A) and MPO activity were determined (B). Each bar 
represents the median (A) or mean ± SEM (B) with 6-8 rats per group. * Significant compared 
to SHAM group, p<0.05; # significant compared to the II/R+Alb group, p<0.05 (by Kruskall-
Wallis/Mann-Whitney). A p-value <0.05 was considered significant. C1-Inh did not reduce 
intestinal mucosal injury. However, MPO activity indicating neutrophil infiltration in the 
intestinal tissue was reduced when C1-Inh was administrated after ischemia. 
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Figure 2. C4b/c, CRP, IgM and anti-Pc IgM levels in the intestinal tissue after I/R and 
effect of C1-Inh. C4b/c (A), CRP (B), IgM (C) and anti-Pc IgM (D) levels in the 
homogenates were measured and corrected for total protein concentration. Each bar represents 
the mean ± SEM with 6-8 rats per group. * Significant from the SHAM group, p<0.05; # 
significant from the II/R+Alb group, p<0.05 (by Kruskall-Wallis/Mann-Whitney). 
Complement activation (A) and increased levels of CRP (B), IgM (C) and anti-Pc IgM (D) 
were found after II/R. C1-Inh administration prior to or after ischemia reduced complement 
activation but did not affect the CRP and IgM levels. C1-Inh administration prior to ischemia 
reduced anti Pc-IgM levels.        
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Figure 3. Immunohistochemical assessment of C3 (A, D), CRP (B, E) and IgM (C, F) in a 
series of  sections of normal intestines (A,  B, C) and intestines subjected to one hour of 
ischemia and 3 h of reperfusion (D, E, F). In the subepithelial space (Ÿ), the intestinal 
mucosa (#) and fragments of tissue in the intestinal lumen (Ƈ), clear staining (arrowheads) is 
shown for C3, CRP and IgM in the rats subjected to intestinal ischemia and reperfusion. Rats 
of the control group show no specific staining. The sections shown are representative for that 
particular experimental group (magnification x 250).    
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Variable 1   Variable 2   Rs*  p-value
C4b/c    CRP    0.769  <0.01 
C4b/c    IgM    0.406  0.133 
C4b/c    anti-Pc IgM   0.334  0.224 
CRP    IgM    0.529  0.043 
CRP    anti-Pc IgM   0.511  0.051
*Rs: Spearman‘s coefficient of correlation  
Table 1. Correlations between the levels of C4b/c, CRP, IgM and anti-Pc IgM present in the 
intestinal homogenates after intestinal ischemia and reperfusion injury. Levels in the 
homogenates were normalized for protein content. Spearman’s rank coefficient of correlation 
(Rs) was used to determine relation between mediators. A p-value < 0.05 was considered 
significant. Increased CRP levels correlated well with complement activation. 
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A  
 Sham (mean, SEM)    I/R (mean, SEM) 
 proximal distal              proximal distal  p-value  
C3 0  0       5.1 (0.9) 24.4 (6.8) 0.0001  
CRP 0  0      13.7 (2.9) 34.1 (7.1) 0.0001 
IgM 0  0    27.5 (3.7)   40.1 (6.2)  0.0001 
Mann-Whitney test two tailed, to compare the percentages of depositions for C3, CRP and 
IgM in the ischemic vs. control group. 
B  
 Sham (mean, SEM)    I/R (mean, SEM) 
 proximal distal              proximal distal  p-value  
C3 0.8 (0.5) 1.2 (0.6)    58.8 (8.0) 81.0 (7.2)       0.0001 
CRP 0           0      78.3 (6.5) 90.0 (3.9)       0.0001     
IgM 4.1(0. 6) 7.5 (3.7)    84.0 (4.2) 93.3 (2.1)       0.0001  
Mann-Whitney test two tailed to compare the percentages of depositions for C3, CRP and  
IgM in the ischemic vs. control group. 
Table 2. Semiquantitative analysis of C3, CRP and IgM deposition in the mucosa (A) and 
in the lumen (B) of the intestines. Extent of the deposition on the proximal and distal part of 
the intestine is expressed as the mean ± SEM of the percentages of positive areas for each 
protein as described in Material and Methods. Two tailed Mann-Whitney test was used, to 
compare the percentages of depositions for C3, CRP and IgM in the ischemic vs. control 
groups. *A p-value <0.05 was considered significant. Complement, CRP and IgM are 
deposited in the mucosa and in the lumen of the jejunum only in the rats subjected to 1h of 
ischemia and 3 h of reperfusion.  
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A 
Proximal part       Rs  p-value n  
_____________________________________________________________________________________________ 
Variable 1            Variable 2 
C3   CRP   -0.005  0.859  16 
C3   IgM    0.051  0.850  16 
CRP   IgM    0.149  0.579  16
Distal part 
_________________________________ _____________________________ 
Variable 1  Variable 2 
C3   CRP     0.508  0.044  16 
C3   IgM    0.380  0.145  16 
CRP   IgM    0.545  0.029  16 
B 
                                                                                                                                                                      
Proximal part     Rs  p-value n  
_____________________________________________________________________________________________ 
Variable 1                  Variable 2 
 C3   CRP   0.750  0.002  14 
 C3   IgM   0.355  0.210  14 
CRP   IgM   0.656  0.008  15
Distal part 
____________________________________________________________________________________________ 
Variable 1  Variable 2 
 C3   CRP   0.698  0.005  14 
 C3   IgM   0.637  0.011  15 
 CRP   IgM   0.863  0.0001  15 
____________________________________________________________________________________________ 
Table 3. Correlations between C3-CRP, C3-IgM and CRP-IgM depositions on intestinal 
ischemic tissue (both II/R groups with Alb). Correlations were calculated using the 
Spearman‘s correlation coefficient (Rs). Sections from the proximal and distal part of the 
intestines were analyzed in the mucosa (A) and in the lumen (B). A p-value < 0.05 was 
considered significant. Ns: not significant. The correlation between C3-CRP, C3-IgM and 
CRP-IgM was stronger in the distal part of the lumen compared to the proximal part of the 
lumen and, compared to both mucosal parts. 
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CHAPTER 5 
Levels of natural IgM antibodies against phosphorylcholine in  
               healthy individuals and in patients undergoing 
                                  isolated limb perfusion  
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Abstract
Natural IgM antibodies against phosphorylcholine (anti-Pc IgM) resemble C-reactive protein (CRP) regarding specificity
and have gained increasing attention because of their supposed role in clearance of damaged cells and in cardiovascular disease.
In order to quantify these antibodies in human plasma, we have developed an ELISA system, in which p-amino-
phenylphosphorylcholine (PCH) coupled to human serum albumin (HSA) was coated on microtiters plates. Human plasma or
serum samples were incubated in the plates, after which bound anti-Pc IgM was detected with mouse anti-human IgM-HRP.
Pre-incubation of Plasma with competitors such as phosphorylcholine, phosphorylethanolamine, phosphorylserine or glycine–
HSA, confirmed that the ELISA was specific for anti–Pc IgM. Levels of anti-Pc IgM in a cohort of healthy donors differed by
more than 100-fold, whereas the fluctuation of anti-Pc IgM levels in individuals over time was small (coefficient of variation
between 6% to 25%). Furthermore, there was no correlation between CRP and anti-Pc IgM in this cohort. Levels of anti-Pc IgM
in the normal donors correlated significantly with IgM binding to apoptotic cells. To test the hypothesis that anti-Pc IgM can
bind to neo-antigens expressed on necrotic or apoptotic cells, anti-Pc IgM was also quantified in patients with tumors
undergoing isolated limb perfusion with tumor necrosis factor-a (TNF-a). Following this procedure, a significant decrease of
circulating anti-Pc IgM relative to total IgM was found in all five patients tested.
0022-1759/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.jim.2004.06.011
Abbreviations: abs, antibodies; anti-Pc IgM, anti-phosphorylcholine IgM antibodies; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride); HSA, human serum albumin; mAb, monoclonal antibody; NHP, normal human plasma; o/n, overnight; oxLDL, oxidized low
density lipoprotein; PBS, phosphate buffered saline, pH 7.4; Pc, calcium salt of phosphorylcholine; PCh, p-aminophenylphosphorylcholine; PE,
O-phosphoryl-ethanolamine; PS, O-phospho-l-serine; rhCRP, recombinant human C-reactive protein; RT, room temperature; strept-PO,
streptavidin-coupled to peroxidase; TNF-a, tumor necrosis factor-a; VB, veronal-buffered saline containing 2 mM CaCl2, 10 mM MgCl2, pH
7.4.
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E-mail address: N.diaz@sanquin.nl (N. Diaz Padilla).
Journal of Immunological Methods 293 (2004) 1–11
www.elsevier.com/locate/jim
78
In conclusion, we have developed a specific and reproducible ELISA for anti Pc IgM quantification. Fluctuation of levels of
these natural antibodies over time in healthy individuals was limited, although the variation among individuals was large.
Significant decreases of levels of anti-Pc IgM were found to occur during tissue damage.
D 2004 Elsevier B.V. All rights reserved.
Keywords: Natural antibodies; Inflammation; ELISA; C-reactive protein
1. Introduction
Antibodies against phosphorylcholine (anti-Pc abs)
have been studied for a few decades and are thought
to constitute a first line defense against infections by
virulent Streptococcus pneumonia and possibly other
bacteria (Briles et al., 1981; Mold et al., 2002). These
antibodies (abs) belong to the class of natural
antibodies (Kantor et al., 1997), and in mice
frequently carry the so-called T15 idiotype, which
initially was identified in an IgA paraprotein secreted
by the plasmacytoma line T (EPC) 15 (Sigal et al.,
1975; Gearhart et al., 1975). More recently, high titers
of anti-Pc abs have been described in hypercholester-
olemic apolipoprotein E-deficient mice that develop
severe atherosclerotic disease (Palinski et al., 1996).
Most of these anti-Pc abs are of the IgM class, and are
produced by CD5+ B1-cells, the predominant B
lymphocytes in the newborn. Further characterization
of these abs revealed that they are structurally and
genetically related, if not identical, to the classic T15
idiotype carrying abs (Kono et al., 1993). Both T15
anti-Pc abs as well as the abs occurring in athero-
sclerotic mice recognize the Pc head group moiety of
phosphatidylcholine in oxidized low density lipopro-
tein particles (OxLDL) (Shaw et al., 2000; Kearney,
2000; Palinski et al., 1996; Friedman et al., 2002).
Both types of abs also bind to oxidized Pc-containing
phospholipids on apoptotic cells but only poorly, if at
all, to native LDL or non-oxidized Pc-containing
phospholipids (Kim et al., 2002).(Chang et al., 1999;
Shaw et al., 2000, 2003; Friedman et al., 2002;
Palinski et al., 1996).
Anti-Pc abs presumably play a role in the patho-
genesis of atherosclerosis although their precise role is
not known (Rose and Afanasyeva, 2003). Among
their supposed functions is blockade of uptake of
OxLDL by macrophages (Horkko et al., 1999).
Accordingly, anti-Pc abs may slow down progression
of atherosclerosis by inhibiting the transformation of
macrophages into foam cells. Recently, Binder et al.
(2003) have shown that circulating levels of natural
anti-Pc IgM in LDL receptor-deficient mice increase
upon vaccination with S. pneumoniae. Importantly,
this immunization attenuated progression of athero-
sclerosis, suggesting a protective effect of anti-Pc IgM
in this murine model.
Based on their supposed role in murine models of
atherosclerosis, studies on the relationship between
circulating levels of anti-Pc IgM and the risk of
cardiovascular disease are warranted. To this end,
specific and reproducible assays for these abs are
needed. In the present study, we developed a specific
and reproducible ELISA for the quantification of anti-
Pc IgM in humans. Using this assay, the distribution
of anti-Pc IgM in a cohort of healthy donors was
estimated. In addition, the correlation between plasma
levels of anti-Pc IgM and those of IgM binding to
apoptotic cells was assessed. Finally, levels of this
IgM were studied in five patients with malignant
tumors undergoing isolated limb perfusion with tumor
necrosis factor-a (TNF-a), to assess whether levels of
anti-Pc IgM decrease in situations of enhanced tissue
destruction.
2. Materials and methods
2.1. Patients and healthy individuals
For the present study, the following sets of plasma
samples were tested: (1) samples from healthy lab
donors obtained at 1-week interval during a period of
6 weeks; (2) samples from healthy blood donors; (3)
serial samples from five patients with a limb tumor
(sarcoma or melanoma) who were treated with
isolated limb perfusion with TNF a (Boehringer
Ingelheim; 4 mg/leg or 3 mg/arm). These patients
participated in studies on the effect of isolated limb
perfusion on local and systemic activation of coagu-
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lation and inflammatory systems (Vrouenraets et al.,
1999). TNF-a was administered during a 3.5-h limb
perfusion. Blood samples were drawn before and at
several times points after the perfusion up to 48 h.
Baseline samples and samples obtained at 24 or 48 h
after the perfusion were used for the present study.
2.2. Collection of blood samples
The blood samples were collected in siliconized
vacutainer tubes containing sodium citrate, EDTA or
sodium heparin (Greiner, Kremsmunster Bad Haller,
Austria). Plasma was obtained after centrifugation at
1300g for 10 min at 4 8C. To obtain recalcified
plasma, sodium citrate or EDTA plasma was recalci-
fied by incubation with 12 mM CaCl2 for 15 min at 37
8C. The formed fibrin clot was removed by centrifu-
gation as described above. Fresh normal human serum
was obtained by collection of blood in glass tubes.
Blood was allowed to clot for 1 h at room temperature
(RT), and centrifuged as described above. Serum and
plasma samples were stored in aliquots at 70 8C.
2.3. Reagents, proteins and antibodies
p-Aminophenylphosphorylcholine (PCh), the cal-
cium salt of phosphorylcholine (Pc), was obtained
from Sigma (St Louis, MO, USA). O-phosphoryle-
thanolamine (PE) and O-phospho-l-serine (PS) were
obtained from Sigma-Aldrich. 1-Ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride (EDC) as
well as gel consisting of immobilized p-aminophenyl-
phosphorylcholine were obtained from Pierce Bio-
technology Perbio (Rockford, IL, USA). The con-
jugation buffer, (2-[N-morpholino] ethanesulfonic
acid) Hydrate (MES) was obtained from Sigma-
Aldrich.
Human serum albumin (HSA) was obtained from
the Business Unit Immune Reagents of our institute
(Sanquin). Recombinant human C-reactive protein
(rhCRP) was from BiosPacific (Emeryville, CA
94608, USA). Streptavidin-coupled to peroxidase
(strept-PO) was purchased from Amersham-Pharma-
cia Biotech (Buckinghamshire, UK). l-C-biotin-N-
hydroxysuccimide ester was from Pierce. Streptavidin
coupled to polymerized horseradish peroxidase was
obtained from the Business Unit Immune Reagents
(Sanquin).
The mouse monoclonal antibody (mAb) against
human CRP (5G4) was produced in our laboratory
(Wolbink et al., 1996) and biotinylated (mAb 5G4bt)
according to established procedures. mAb M15
against human IgM, coupled to horseradish perox-
idase or to biotin, was obtained from the Business
Unit Immune Reagents (Sanquin).
2.4. ELISA for anti-Pc IgM antibodies
p-Aminophenylphosphorylcholine was coupled to
HSA according to the procedure provided by Pierce
(Pierce Biotechnology, www.piercenet.com). Briefly,
4 mg of HSA was coupled to 4 mg of PCh in 0.1 M
MES buffer, pH 4.5, containing 2 mg of EDC in a
final volume of 1.6 ml. The mixture was incubated for
2 h at RT. The conjugated HSA was then dialyzed
against phosphate buffered saline, pH 7.4 (PBS), at
4 8C (Pc–HSA). As a control, glycine instead of PCh
was coupled to HSA (glycine–HSA).
Polystyrene microtiter plates (Dynatech, Plochin-
gen, Germany) were incubated o/n at 4 8C with Pc-
HSA (2.5 Ag/ml) in 0.1 M carbonate/bicarbonate
buffer, pH 9.6. Glycine–HSA was also included as a
control. Final volume of this as well as of all other
steps was 100 Al per well, unless stated otherwise.
After washing the plates twice with PBS, residual
binding sites were blocked (1 h at RT) with 200 Al per
well of PBS containing 2%, w/v, HSA. Human
plasma or sera were appropriately diluted in assay
buffer (veronal buffer containing 0.1%, w/v, HSA, 2
mM CaCl2, 0.1%, w/v, Tween 20, pH 7.4), and
incubated for 1 h at RT. After this and the subsequent
incubation steps, the plates were washed with PBS
containing 0.1%, w/v, Tween-20. IgM bound to Pc-
HSA was quantified with peroxidase-labeled anti-
human IgM mAb diluted in assay buffer. Finally,
peroxidase activity was visualized by incubation with
3,3V, 5,5V-tetra-methyl-benzidine, 100 Ag/ml in 0.11
M sodium acetate, pH 5.5, containing 0.003%, v/v,
H202. The reaction was stopped after 10 min by
addition of 2 M H2S04, and the absorbance at 450 nm
was measured in a Titertek plate reader.
Dilutions of a pool of normal plasma, obtained
from 40 healthy volunteers, were used to generate a
standard curve in each microtiter plate. This standard
was arbitrarily proposed to contain 100 U per ml of
anti-Pc IgM antibodies. Results with plasma samples
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were related to this standard and expressed as U/ml of
anti-Pc IgM.
The specificity of the binding of anti-Pc IgM to
Pc-HSA was determined by competition immuno-
assay. The standard curve was pre-incubated with
increasing amounts of the competitors (Pc, PE, and
PS) or glycine–HSA. After 1-h incubation, the
standard with or without competitors was added to
the Pc-HSA-coated plates and tested as described
above. As another control, four normal sera were
diluted 1 to 2 in VB, and absorbed batchwise onto
PCh-Sepharose gel (1 volume of 1:2 diluted serum,
with 1 volume of Sepharose suspension (capacity 5–
11 mg of human CRP per ml gel, 5 ml gel and 5 ml
buffer) o/n at 4 8C. Glycine-Sepharose was used as a
negative control. The supernatants were then tested in
the ELISA.
2.5. Binding of CRP to Pc-HSA-coated plates
Plates with Pc-HSA were prepared as described
above, and incubated with recalcified NHP or rhCRP
diluted in assay buffer (see previous paragraph) for 60
min at RT. After a washing procedure, bound CRP
was detected by incubation for 60 min with biotiny-
lated mAb 5G4 against human CRP (mAb 5G4bt),
diluted in assay buffer followed by a subsequent
incubation with polymerized peroxidase dissolved in
veronal buffer containing 2 mM CaCl2 and 2%, v/v,
milk (Campina, The Netherlands). Finally, peroxidase
activity was visualized with tetra-methyl-benzidine as
described above. As a control, sample incubations
were prepared in the presence of 10 mM EDTA.
2.6. Quantification of total IgM
The concentration of total IgM was determined by
nephelometry (Behring Nephelometer Analyzer, Mar-
burg, Germany), according to standard procedures.
2.7. ELISA for human CRP
CRP concentration was determined by ELISA as
described (Wolbink et al., 1996). Briefly, polyclonal
rabbit anti-human CRP (KH61) was used as capture
abs and mAb 5G4bt was used as the detecting
antibody. Results were obtained by reference to a
standard from Behringwerke (Marburg, Germany).
2.8. Binding of IgM to apoptotic cells
Levels of IgM binding to apoptotic cells were
assessed with FACS using Jurkat cells as previously
described (Zwart et al., 2004). Briefly, Jurkat cells were
made apoptotic by incubation with etoposide (Sigma).
Cells were washed with serum-free medium and
incubated with 10%, v/v, recalcified human plasma
for 30 min. IgM binding to the cells was assessed by
incubation with biotin-labeled anti-human IgM mono-
clonal antibody. Results were analyzed by flow
cytometry, and expressed as mean fluorescence inten-
sity (MFI). Plasma samples were also tested with vital
Jurkat cells, as a control. Under the conditions used,
binding of IgM to these vital cells was negligible.
2.9. Statistical analysis
Data were analyzed with the GraphPad software
Prism (San Diego, CA, USA). The distribution of anti-
Pc IgM in healthy donors was analyzed using a
normality test. Groups of data were compared with
repeated measures ANOVA. The variation of levels of
anti-Pc IgM and CRP was evaluated by comparing
intra-individual variation over time with the paired
Student’s t-test (two-tailed). Correlations between
parameters were assessed by estimating Spearman’s
rank correlation coefficient. A two-sided p-value b0.05
was considered to indicate statistical significance.
3. Results
3.1. Quantification of anti-Pc IgM with ELISA
To quantify natural IgM antibodies against phos-
phorylcholine in humans, an ELISA was developed
using PCh coupled to HSA as capture antigen on the
plates. The coating antigen was validated by assessing
binding of CRP, which has a similar specificity as
anti-Pc IgM (Tillet and Francis, 1930; Thompson et
al., 1999; Volanakis and Kaplan, 1971; Chang et al.,
2002). Upon incubation of the plates with rhCRP or
NHP, calcium-dependent binding of CRP was
observed to Pc-HSA plates but not to glycine–HSA
plates (data not shown). Thus, Pc-HSAwas probably a
suitable antigen for anti-Pc IgM. This was further
assessed by incubation of Pc-HSA plates with serial
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dilutions of NHP followed by detection of bound IgM
with peroxidase–labeled anti human IgM mAb. A
dose-dependent binding of IgM was observed (Fig.
1A). In general, IgM is notorious for antigen non-
specific sticking to solid phases. Hence, we included a
number of controls to rule out the possibility that the
observed binding of IgM to Pc-HSA was specific.
Binding of IgM to HSA- or non-coated plates upon
incubation with dilutions of NHP was negligible.
However, significant binding of IgM to glycine–HSA
was observed, though this binding was less than that
to Pc-HSA-coated plates (Fig. 1A). We did competi-
tion experiments to further substantiate the specificity
of the ELISA for anti-Pc IgM. Binding of IgM to Pc-
HSA-coated plates was almost completely inhibited in
the presence of increasing concentrations of Pc during
the sample incubation, whereas PE, PS or glycine–
HSA had no effect (Fig. 1B). Conversely, binding of
IgM to glycine–HSA was inhibited by glycine–HSA
but not by Pc, PE or PS (data not shown). In addition,
four sera absorbed onto PCh-Sepharose yielded
negative results in the ELISA with Pc-HSA-coated
plates, whereas the same sera absorbed onto glycine-
Sepharose exhibited unaffected IgM binding to Pc-
HSA-coated plates (Fig. 1C). Thus, these experiments
together demonstrated the specificity of the ELISA
with Pc-HSA-coated plates for anti-Pc IgM.
We next tested the effect of the method of blood
collection, and of freezing and thawing of samples, on
levels of anti-Pc IgM as measured with the ELISA. In
Table 1 it can be seen that anti-Pc IgM levels were
similar in plasma samples collected in EDTA, sodium
citrate or in sodium heparin, as well as in serum
samples. Moreover, Table 1 also shows that five
additional cycles of freezing at 70 8C and thawing
did not affect levels of anti-IgM. We also tested with
plasmas from 10 different donors whether binding of
IgM in the Pc-HSA ELISA was calcium-dependent.
The results showed no difference in levels when
Fig. 1. Specificity of the ELISA for anti Pc IgM antibodies. (A)
Microtiter plates were coated with Pc-HSA (n) glycine–HSA (x)
HSA (E) or coating buffer (5). Dilutions of pooled normal human
plasma were then added to the plates. Bound IgM was detected
using peroxidase labeled anti-human IgM mAb. Peroxidase activity
was visualized with TMB. (B) Pooled normal human plasma was
pre-incubated for 1 h with Pc (n), PE (E), PS (.) or glycine–HSA
(x), and tested in the ELISA. (C) Four sera were absorbed onto Pc-
Sepharose and tested in the ELISA. Bars represent the amount of
specific IgM against Pc relative to the total IgM (U/g) in the sera
absorbed with Pc-Sepharose (open bars), glycine-Sepharose (black
chequered bar), or without absorption (black bar). Results in the
figures are the means of triplicate determinations. The experiments
were repeated twice with similar results.
Table 1
Repeated freezing/thawing has no effect on levels of anti-Pc IgM in
plasma or serum samples
Sample t1 t6
EDTA 141.91F28.63 145.08F28.13
Citrate 128.39F21.74 117.15F19.57
Heparin 139.58F22.17 143.16F24.35
Serum 133.96F23.85 151.13F29.43
Values represent meanFS.E.M. of the anti-Pc IgM concentration in
U/ml of six healthy donors.
EDTA, citrated or heparin plasma or serum samples were frozen at
70 8C and thawed one (t1) to six (t6) times, and then tested in
ELISA.
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EDTA was present during the sample incubation step
(data not shown).
3.2. Variation of anti-Pc IgM levels in healthy donors
To quantify results obtained with plasma samples,
a pool of plasma samples from healthy donors was
arbitrarily assigned 100 U of anti-Pc IgM per ml.
Results with samples to be tested were then compared
with this plasma pool and expressed as U/ml. In 40
healthy donors, the median concentration of anti-Pc
IgM was 108 U/ml, the 25th percentile being 55 U/ml,
and the 75th percentile 162 U/ml. The lowest
concentration of anti-Pc IgM in these healthy donors
was 3 U/ml and the highest was 469 U/ml. Thus,
levels of anti-Pc IgM in the healthy donors differed
considerably, i.e. more than 100-fold. The distribution
of anti-Pc IgM in the donors according to age is
shown in Fig. 2A, and that according to sex is shown
in Fig 2B. Younger or older persons had similar levels
of anti-Pc IgM. Moreover, men had similar levels as
women. To estimate variation of anti-Pc IgM levels
over time, plasma samples from 20 healthy donors
were collected weekly during a period of 6 weeks, and
tested for anti-Pc IgM with the ELISA. Small
fluctuations in anti-Pc IgM levels were observed
(coefficient of intra-individual variation over time:
6–25%; Fig. 3A). For comparison, CRP plasma levels
were also measured in the same samples and appeared
to differ significantly (pb0.0001) more during the
observation period of 6 weeks than anti-Pc IgM levels
(coefficient of intra-individual variation over time for
CRP: up to 114%; Fig. 3B). These differences in
variation of plasma levels of anti-Pc IgM CRP were
not explained by different reproducibility of the
assays, since the coefficient of inter-assay variation
was less than 10% for either assay.
Because of the functional similarities (specificity for
PC; complement activation) between anti-Pc IgM and
CRP, we studied the correlation between levels of either
parameter in the healthy individuals. However, the
levels of anti-Pc IgM and CRP, did not correlate
(Spearman’s r: 0.115, p=0.2429). Furthermore, we also
assessed the relationship between anti-Pc IgM and total
IgM concentration. These parameters showed only a
borderline correlation (Spearman’s r 0.44; p=0.051).
3.3. Anti-Pc IgM in healthy donors correlate with IgM
binding to apoptotic cells
IgM with specificity for Pc has been shown to bind
to apoptotic cells (Kim et al., 2002; Chang et al.,
1999, 2002; Shaw et al., 2000). In order to examine
the relation between levels of natural IgM abs as
measured with Pc-HSA-coated plates, and IgM bind-
ing to apoptotic cells, 30 sera were tested both in the
anti-Pc IgM ELISA as well as for binding of IgM to
apoptotic Jurkat cells. As seen in Fig. 4, anti-Pc IgM
correlated positively with the amount of IgM that
bound to the apoptotic cells (pb0.0001).
3.4. Circulating levels of anti-Pc IgM antibodies
decrease during tissue damage
We postulated that during tissue damage, neo-
antigens are exposed on the membranes of jeopardized
cells, which may be recognized by the anti-Pc IgM
antibodies. Consequently, a decrease in plasma levels
of anti-Pc IgM is expected in situations of sufficient
tissue damage. To test this hypothesis, the kinetics of
anti–Pc IgM in plasma samples from five patients
undergoing isolated limb perfusion with TNFa
because of sarcoma or melanoma was determined. In
Fig. 2. Distribution of anti-Pc IgM in healthy controls according to
age (A) or sex (B).
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Fig. 3. Fluctuation of individual levels of anti-Pc IgM over time. Anti-Pc IgM (A and B) and CRP concentrations (C and D) were measured in
plasma obtained weekly from healthy controls.
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all patients, regression of the tumor was observed, and
was accompanied by high levels of several pro-
inflammatory cytokines such as IL-6 (data not shown).
The anti-Pc IgM concentration was related to total IgM
levels in order to adjust for hemodilution. A moderate
decrease of anti-Pc IgM levels was observed in all
patients at 24 h after perfusion ( pN0.05). At 48 h after
perfusion, this decrease was up to 60% and had
become significant (pb0.05; Fig. 5).
4. Discussion
Some decades ago, anti-Pc IgM was considered to
constitute a first-line defense against microorganisms.
More recently, interest in these antibodies was
renewed because of their potential involvement in
processes such as atherosclerosis (Binder et al., 2003;
Nilsson et al., 1997; Palinski et al., 1995, 1996; Wu et
al., 1998) or removal of apoptotic cells and cellular
debris (Kim et al., 2002). As a consequence, levels of
anti-Pc IgM may constitute a risk marker for human
diseases such as cardiovascular disease (Rose and
Afanasyeva, 2003). Here we describe a specific and
reproducible ELISA for the quantification of anti-Pc
IgM. Levels of these antibodies differed by more than
100-fold among healthy donors, whereas the intra-
individual variation over time was limited. Further-
more, anti-Pc IgM levels correlated well with IgM
binding to apoptotic Jurkat T cells and decreased in
patients with sarcoma or melanoma upon isolated
limb perfusion with TNF-a.
Quantification of IgM with ELISA in general is
associated with an increased risk of non-specific
binding of IgM to the plates. However, the ELISA
for the quantification of natural anti-Pc IgM in
humans described here was considered specific since
the signal was abolished when plasma was pre-
incubated with Pc, but not PE or PS. In addition,
pre-absorption of sera with Pc-Sepharose reduced
IgM binding in the ELISA. Furthermore, pre-incuba-
tion of plasma with modified albumin (glycine–HSA)
did not affect the response of plasma samples in the
anti-Pc IgM ELISA, ruling out the possibility that
IgM detected in this assay had interacted with the
chemical linker used to prepare Pc-albumin. Thus, the
IgM detected in the ELISA was IgM specifically
binding to Pc. A limitation of the use of Pc-albumin as
a coating antigen in the ELISA is that Pc conjugated
Fig. 4. Relationship between anti-Pc IgM and IgM binding to
apoptotic cells in healthy individuals. Anti-Pc IgM and IgM binding
to apoptotic Jurkat cells were measured in samples from 30 healthy
donors with ELISA and FACS, respectively. The concentration of
anti-Pc IgM is expressed in U/ml and IgM binding to apoptotic cells
is presented as mean fluorescence intensity (MFI).
Fig. 5. Levels of anti-Pc IgM before and after limb perfusion with TNFa. Isolated limb perfusion with TNFa was performed in five patients with
sarcomas during 3.5 h. Systemic blood samples were taken before (t0, black bars) and after perfusion, 24 h (grey bars) and 48 h (open bars). The
concentration of anti-Pc IgM was adjusted to total IgM concentration quantified by nephelometry as described in the Materials and methods.
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to HSA may not resemble Pc presented by injured
cells. However, CRP, which has a well-known
specificity for Pc (Volanakis and Kaplan, 1971;
Thompson et al., 1999) and is able to bind to
apoptotic and injured cells (Gershov et al., 2000;
Chang et al., 2002), easily bound to the Pc-HSA.
Thus, Pc conjugated to HSA resembled Pc exposed on
apoptotic or injured cells. This was confirmed by the
observation that levels of anti-Pc IgM in healthy
donors correlated with IgM binding to apoptotic cells.
Studies on the relationship between biochemical
markers and cardiovascular events are more credible
when markers to be measured in blood samples are
stable during repeated freezing and thawing. As with
anticardiolipin IgM (Brey et al., 1994), we found no
significant difference in mean concentration of anti-Pc
IgM after repeated freeze–thaw cycles.
Notably, the levels of anti-Pc IgM differed by more
than 100-fold among healthy donors, though there
was no relationships between these levels and age or
sex. In animal models for atherosclerosis anti-Pc IgM
increase over time (Binder et al., 2003). Our data do
not support the notion that anti-Pc IgM in humans is
increased in atherosclerosis since in that case, some
relationship between plasma levels and age would be
expected. Conversely, anti-Pc IgG1 was significantly
higher in children than in adults (Freijd et al., 1988).
In addition, anti-Pc IgM levels did not correlate with
total IgM concentration, as has been found earlier for
anti-Pc IgG (Freijd et al., 1988). We speculate that the
inter-individual differences in anti-Pc IgM levels
among healthy donors reflect genetic variations as
well as exposure to different microbes during life.
Anti-Pc IgM and CRP share similarities in bio-
logical function in that they can bind to Pc exposed on
injured cells and activate complement (Gershov et al.,
2000; Pepys and Hirschfield, 2003). Nevertheless,
plasma levels of these moieties did not correlate with
each other. Hence, one can speculate that IgM and
CRP constitute two independent mechanisms taking
care of injured cells. The relative contribution of anti-
Pc IgM and CRP to complement activation could
differ between individuals depending of their relative
concentration. Indeed, we (Krijnen et al., unpublished
observations) have recently shown that the relative
amounts of CRP and IgM deposited on cardiomyo-
cytes in infarcted myocardium may differ from patient
to patient.
Complement activation by apoptotic cells in
plasma is mainly mediated by IgM binding to neo-
epitopes exposed in the membranes of these cells
(Kim et al., 2002) (Zwart et al., 2004). Though it
has been claimed that most if not all of these IgM
antibodies recognize Pc exposed in the lysophos-
phatidylcholine in the cell membrane (Kim et al.,
2002), we have observed that this only holds for
some individuals, whereas others also have IgM
recognizing additional, unknown epitopes (Ciurana
and Hack, in press). In this study, we report a good
correlation between the levels of anti-Pc IgM as
measured by ELISA and the amount of IgM binding
to apoptotic Jurkat cells. This finding is consistent
with the notion that part of the IgM binding to
apoptotic cells recognizes Pc. The specificity of the
rest of the IgM recognizing apoptotic cells is
currently under investigation.
To further verify that anti-Pc IgM can bind to
apoptotic or damaged cells, we measured plasma
levels of these antibodies in patients with sarcoma or
melanoma and treated by isolated limb perfusion with
TNF-a. Most of these patients respond well to this
therapy within a few days (van Ginkel et al., 1996;
Koizumi et al., 2003), and exhibit massive death of
both malignant cells and endothelial cells of the tumor
vasculature. Ischemia and subsequent reperfusion of
the perfused limb may also add to cell death. A
decrease of anti-Pc IgM relative to total IgM levels
was observed in all of the patients tested, in agreement
with the notion that anti-Pc IgM can bind to oxidized
or hydrolyzed phospholipids of damaged cells. We
speculate that this mechanism contributes to the
clearance of damaged cells and cellular debris.
In conclusion, we describe a specific and reprodu-
cible ELISA for anti-Pc IgM. Levels of this IgM differ
by up to 100-fold among healthy persons. Future
studies on anti-Pc IgM should delineate its role in
human diseases such as cardiovascular disease.
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Relation of IgM antibodies against apoptotic cells and       
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Abstract 
Background: Natural IgM antibodies, particularly anti-phosphorylcholine IgM (anti-PCh 
IgM), are suspected to be involved in cardiovascular disease as they possibly modulate 
atherosclerosis or acute myocardial infarction (AMI). Aim: To assess the relationship between 
plasma levels of anti-PCh IgM and IgM that binds to damaged cells, with infarct size or post-
infarct inflammatory responses in patients with AMI. Methods: Plasma samples from 50 
patients with AMI and 46 healthy controls were analysed. IgM binding to damaged cells was 
measured by incubating plasma samples with apoptotic Jurkat cells with subsequent detection 
of bound IgM by fluorescence activated cell sorter (FACS). Anti-PCh IgM was measured with 
a specific ELISA. The post-infarct inflammatory response was quantified by measuring C-
reactive protein (CRP), secretory phospholipase A2 (sPLA2), IL6, IL8 and activated 
complement. Results: On admission, patients with AMI had similar levels of IgM binding to 
apoptotic cells but lower levels of anti-PCh IgM, also when corrected for hemodilution, than 
healthy controls. These levels were constant during 48 hours. To analyse the relation of IgM 
species to apoptotic cells and inflammatory or clinical parameters, patients with levels above 
the median were compared to those with levels below the median. Patients with higher levels 
of IgM binding to apoptotic cells had similar inflammatory responses and infarct size as those 
with lower levels. Patients with higher levels of anti-PCh IgM, however, had larger infarcts as 
assessed with ECG, and a more pronounced response of the acute phase protein sPLA2. 
Conclusion: Plasma levels of natural IgM, in particular anti-PCh IgM, may modify 
inflammatory responses and infarct size in patients with acute myocardial infarction.
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Introduction 
Patients with acute myocardial infarction (AMI) frequently develop fever and have increased 
plasma levels of cytokines and acute phase proteins such as C-reactive protein (CRP) and 
secretory phospholipase A2 (sPLA2) in the first days following the onset of infarction. Thus, 
myocardial infarction induces an inflammatory response in the ischemic tissue which may 
lead to systemic symptoms. Indeed expression of cytokines and infiltration of 
polymorphonuclear granulocytes (PMN) occurs in the jeopardized myocardium during 
infarction [1-4]. Furthermore, acute phase proteins such as CRP and sPLA2 are deposited in 
the infarcted myocardium and the complement system is activated locally [5-7]. 
Cardiomyocytes in the ischemic area may show evidence for apoptosis [8]. To what extent 
this post-infarct inflammatory response in the heart contributes to the infarct size in humans is 
unknown. Animal studies suggest that this contribution may be substantial [9]. 
 Though local ischemia obviously is the primary stimulus for the inflammatory changes 
ensuing in the infarcted myocardium, the molecular mechanisms explaining the link between 
ischemia and inflammation are far from clear. Possibly, changes in membrane phospholipids 
such as oxydation, hydrolysis and membrane flip-flop due to the formation of oxygen 
radicals, the decrease of intracellular ATP and the increase of intracellular calcium, stimulate 
the binding of extracellular proteins such as sPLA2 and CRP [10;11], which in turns activate 
complement thereby triggering inflammation. Some evidence suggests that also natural IgM 
antibodies may be among proteins that bind to altered phospholipids in the membranes of 
ischemic cells, and via subsequent activation of complement contribute to the post-infarction 
inflammatory response. For example, studies in knock-out mice have convincingly shown that 
natural IgM is involved in ischemia-reperfusion injury by binding to ischemic endothelial 
cells and by triggering reperfusion-induced complement activation [12]. The specificity of this 
IgM is still unknown. In immunohistochemical studies we recently observed that IgM 
becomes deposited in the ischemic myocardium during infarction in humans who died from 
AMI. This IgM is co-localized with CRP and activated complement [13]. Thus, in humans 
IgM, in addition to CRP [5;6] and possibly other molecules, may contribute to local 
complement activation in the ischemic myocardium. The nature of this IgM is also unknown.  
 A number of studies have shown that IgM present in normal serum can bind to 
apoptotic cells [14;15], including natural IgM against phosphorylcholine (anti-PCh IgM) [16]. 
In the present study we tested the hypothesis that IgM that binds to damaged cells and or anti-
PCh IgM may enhance the post-infarct inflammatory response in patients with AMI. To test 
this hypothesis, we developed an assay to measure plasma IgM that binds to apoptotic cells, 
and we used this assay, as well as an ELISA for anti-PCh IgM, to measure plasma levels of 
this IgM in patients with AMI. These levels were compared to those in healthy controls and 
were also related to parameters for cardiac damage and of inflammatory mediators such as 
IL6, IL8 and activated complement. 
Patients, material and methods  
Blood samples 
Blood samples from 50 patients with AMI were collected in 10 mM EDTA, final 
concentration, at various time points after admission to the hospital. Samples were centrifuged 
at 1300 g after which the supernatant was stored in aliquots at -70ºC until tested. All patients 
fulfilled the criteria for AMI, which included typical chest pain, typical electrocardiographic 
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abnormalities in combination with elevated cardiac markers such as creatine-kinase (CK) 
[17]. Infarct size was calculated from the cumulative release of lactate dehydrogenase (LDH) 
or CK [18;19], and also from electrocardiographical infarct scores (Selvester scores) in 
patients with a first AMI before therapy [20;21]. Patients had participated in earlier studies on 
the role of complement in AMI. All patients had given informed consent. The study was 
approved by the Medical Ethical committee of the VU Medical Centre. 
 Plasma samples from a group of 46 healthy donors were collected and processed in the 
same way. In addition, serial samples were obtained from 5 healthy donors weekly for a 
period of 6 weeks. During this period none of the volunteers suffered from an intercurrent 
illness.  
Proteins and antibodies 
Anti-human IgM monoclonal antibody (mAb) MH-15 (IgG1 subclass) was obtained from 
Sanquin, Business Unit Reagents (Amsterdam, The Netherlands). The mAb was biotinylated 
with LC-biotin-n-hydroxysuccinimide ester (Pierce, Rockford, IL) according to the 
manufacturer’s instructions. AnnexinV-FITC and propidium iodide (PI) were obtained from 
Bender Med System (Vienna, Austria) and streptavidin-allophycocyanin (Strep-APC) 
conjugate was obtained from BD Biosciences Pharmingen (San Diego, CA). Human serum 
albumin (HSA), purchased at Sanquin Business Reagent and p-aminophenylphosphoryl-
choline (Sigma Chemicals Co., St Louis, MO) were coupled following a protocol described 
earlier [22].
Assay for IgM binding to late apoptotic cells (apo-IgM)  
Jurkat cells were cultured in IMDM supplemented with 5%, v/v, heat-inactivated foetal calf 
serum (Bodinco, Alkmaar, The Netherlands), 20 μg/ml human apo-transferrin (Sigma), 100 
U/ml penicillin and 100 μg/ml streptomycin (Life Technologies, Grand Island, NY) at 37°C in 
a humidified atmosphere (5%, v/v, CO2 / 95% air). Apoptosis was induced in Jurkat cells by 
incubation in 96 wells round-bottom plates at 2.5 x105 cells per well in serum-free IMDM 
containing 100 μM etoposide (Sigma) for 48 hours at 37ºC. After apoptosis induction, cells 
were washed with serum-free culture medium to remove etoposide and incubated with various 
amounts of plasma in veronal buffered saline, pH 7.4 (VB), containing 10 mM CaCl2 and 2 
mM MgCl2 (VB++), final volume 100 μl. Plasma samples from patients were tested in this 
system at a concentration of 5%, v/v, unless otherwise indicated. After an incubation for 30 
minutes at 37°C, cells were washed thrice with Hepes buffer containing calcium (Hepes 10 
mM, NaCl 150 mM, KCl 5 mM, CaCl2 1.8 mM and MgCl2 1 mM, pH 7.4) and incubated with 
biotin-labelled monoclonal anti-IgM (5 μg per ml in 50 μl of hepes buffer, final volume) for 
30 minutes at 4°C in darkness. After a second washing procedure, cells were incubated with 
streptavidin-APC (1 to 750 diluted) or annexin-V-FITC (1 to 100 dilution) in 100 μl final 
volume for 30 minutes at 4°C in darkness. After washing with Hepes buffer, cells were 
resuspended in Hepes buffer containing calcium as well as PI (at a final concentration of 500 
ng per ml). Results were analysed by flow cytometry, and expressed as mean fluorescence 
intensity (MFI). Data were stored in Cellquest acquisition program and analysed with 
WinMDI 2.8 program.
ELISA for anti-phosphorylcholine IgM 
IgM antibodies directed against phosphorylcholine (PCh) were measured by specific ELISA 
as described [22]. Briefly, p-aminophenylphosphorylcholine coupled to human serum albumin 
(PCh-HSA; 2.5 µg/ml in 0.1 M carbonate/bicarbonate buffer, pH 9.6) was coated onto 
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polystyrene microtiter plates (Dynatech, Plochingen, Germany) overnight at 4°C. After 
washing the plates twice with PBS, residual binding sites were blocked (1 hour at room 
temperature) with 200 µl per well of phosphate buffered saline, pH 7.4 (PBS) containing 2 %, 
w/v, HSA. Human plasma or sera were appropriately diluted in assay buffer (veronal buffer 
containing 0.1 %, w/v, HSA, 2 mM CaCl2, 0.1 %, w/v, Tween 20, pH 7.4), and incubated for 
1 hour at room temperature. Thereafter, the plates were washed with PBS containing 0.1 %, 
w/v, Tween-20. IgM bound to PCh-HSA was quantified with peroxidase-labelled anti-human 
IgM mAb diluted in assay buffer. Finally, peroxidase activity was visualized with tetra-
methyl-benzidine. Dilutions of a pool of normal plasma, obtained from 40 healthy volunteers, 
were used as standard curve in the assay. This standard was arbitrarily said to contain 100 U 
per mL of anti-PCh IgM antibodies. Results of plasma samples were related to this standard 
and expressed as U of anti-PCh IgM per mL.  
Biochemical and inflammatory parameters 
IgM concentration was assessed with a nephelometric assay. Secretory phospholipase A2
(sPLA2), CRP, interleukins-6 and -8 (IL6 and IL8, respectively), and activated complement 
fragments C4b/c and C3b/c were determined with specific ELISA as described earlier [23-27]. 
Note that the ELISAs do not discriminate between C4b, C4bi or C4c, and C3b, C3bi and C3c, 
and that the activation products detected by these assays are hence referred to as C4b/c and 
C3b/c, respectively. Results were expressed as μg/L (sPLA2)[23], mg/L (CRP) [24], ng/L 
(IL8 and IL6) [25;26]  and nmol/L (C3b/c and C4b/c) [27]. LDH and CK concentrations were 
determined in the routine clinical chemistry laboratorium of the VU Medical Centre. 
Analysis of data 
Data were analysed with Graph Pad Instat® (version 3.0). Distribution of data was analysed 
with the method of Kolmogorov and Smirnov. When normally distributed, data were analysed 
with Student’s t test or one-way analysis of variance (ANOVA) multiple comparison test with 
Bonferroni. Correlation between parameters was assessed by calculating the Pearson’s 
correlation coefficient. In case of non-normal distribution, Mann-Whitney’s and Kruskal-
Wallis with Dunn’s multiple comparison tests were used to assess differences between 
groups. A P-value <0.05 was considered to represent a significant difference or correlation. 
Results
Patients included 
The patients with AMI, 8 females and 42 males, included in the analysis had a median age of 
60 years, range 34 to 76 years. Seventy % of the patients were treated with thrombolytic 
agents, 20% with acute percutaneous transluminal coronary angioplasty. Twenty-four patients 
had a first infarction; the others had suffered from a myocardial infarction before. None of the 
patients had an underlying illness, none died during the observation period. 
IgM binding to apoptotic cells 
IgM that binds to damaged cells was measured by incubating apoptotic Jurkat cells with 
plasma samples, and detection of bound IgM with FACS [15]. A triple staining procedure 
allowed the determination of specific IgM that bound to the late apoptotic population, which 
was identified by its characteristic side and forward scatter dot plot (figure 1A), and by its 
capacity to bind annexinV and propidium iodide (figure 1B). IgM bound to the cells was then 
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assessed with the third marker, streptavidin-APC that bound to biotinylated anti-IgM (figure 
1C). Thus, the mean fluorescence intensity (MFI) of the streptavidin-APC of the gated 
population was determined as a measure for IgM binding to apoptotic cell (anti-apo IgM). 
Cells not incubated with plasma were used as control for aspecific staining (figure 1D). IgM 
binding to apoptotic cells appeared to vary among donors. For example, figure 1D shows the 
results, expressed as MFI, obtained when plasma samples from 2 different healthy donors 
were tested. 
Figure 1: IgM binding to apoptotic cells. Apoptosis was induced in Jurkat cells as described 
in material and methods. Cells were subsequently incubated with plasma. After selection of 
the late apoptotic population (encircled) by specific side and forward scatter (A), and 
identification of apoptotic cells with annexin V and propidium iodide positive, (encircled) (B), 
IgM bound to the cells was detected with biotinylated anti-IgM mAb and streptavidin-APC 
(C). (D) Histograms showing IgM binding to apoptotic cells using 2 plasma samples from 
fluorescence intensity (MFI). Cells incubated without plasma are indicated by the filled 
histogram. 
To get insight into the variation in time of levels of anti-apo IgM, plasma samples were 
obtained weekly from 5 healthy lab donors during a period of 6 weeks, and measured for anti-
apo IgM. Intra-individual levels of anti-apo IgM hardly varied during this period with a 
variation coefficient (CV) of 11 % ± 1.0, (figure 2). Previously we have observed that the 
variation of levels of anti-PCh IgM in time is also limited in healthy individuals [22]. In order 
to reduce assay variation as much as possible, all plasma samples were tested within the same 
experiment.  
A    B 
   
C    D 
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Figure 2: Variation of IgM binding to apoptotic cells in time. Apoptotic Jurkat cells were 
incubated with plasma samples taken weekly from 5 healthy donors for a period of 6 weeks. 
IgM binding to apoptotic population was detected as described in material and methods and 
expressed as mean fluorescence intensity. 
Anti-apo IgM and anti-PCh IgM  in the AMI patients 
Levels of anti-apo IgM were determined as described above in blood samples from patients 
with AMI or from healthy controls (figure 3). Levels were somewhat lower in the AMI 
patients as compared to those in the healthy controls (230 MFI ±34, mean ±sem, n=50, versus 
264 MFI ±24, n=46; p<0.05). Moreover, levels of anti-apo IgM 48 hours after the onset of 
complaints had further decreased compared to those on admission (169 MFI ±15 versus 230 
MFI ±34, n=45; p<0.001). These differences in levels between patients and controls, however, 
were lost when levels were corrected for hemodilution by calculating the ratio of anti-apo IgM 
to total IgM (patients t=0: 93 ±8 and 114 ±10 at t=48, versus healthy controls 86 ±5, figure 
4A). 
 In addition to anti-apo IgM we also determined the concentration of anti-PCh IgM by 
ELISA as described in materials and methods. Similarly as for anti-apo IgM, values were 
corrected for hemodilution by estimating the ratio of anti-PCh IgM to total IgM. Although 
there was no significant difference between the ratios of the patients on admission versus 
those at 48 hours (84 ±7, mean ±sem, versus 87 ±10, respectively), the ratio at either time 
point was significantly lower than that in the control group of healthy donors (141 ±17, 
respectively p<0.01 and p<0.001, figure 4B). 
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Figure 3: Anti-apo IgM in patients with myocardial infarction and controls. Apoptotic 
Jurkat cells were used to measure levels of anti-apo IgM. Plasma samples from patients on 
admission (t=0; n=50) or 48 hours later (t=48; n=45), and from healthy  controls (n=46) 
were   tested for anti-apo IgM as described in material and methods. Levels are expressed as 
MFI, data were analysed with Kruskal-Wallis and Dunn’s multiple comparison test. *P<0.05 
and ***P<0.001.  
Figure 4: Anti-apo IgM (A) and anti-PCH IgM (B) in patients with myocardial infarction.
Levels were corrected for hemodi-lution by assessing the ratio of anti-apo IgM to total IgM 
(A) and of anti-PCh IgM to total IgM (B). Levels on admission (t=0) and at 48 hours (t=48) 
are given for the patients, as are the ratios measured in healthy controls.  Data were analysed 
with Kruskal-Wallis and Dunn’s multiple comparison test. *P<0.05, **P<0.01 and 
***P<0.001. 
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Relation of anti-apo IgM or anti-PCh IgM with infarct size 
Infarct size in the patients was estimated from the course of LDH and CK-MB. This course 
was quantified by calculating a cumulative concentration over the first 48 hours after the onset 
of complaints [18]. To establish the relation of levels of anti-apo IgM or anti-PCh IgM to 
infarct size, we compared the cumulative release of LDH or CK-MB in patients with anti-apo 
IgM levels lower or higher than the median value at the onset of the infarction (Table 1 and 
figure 5 A, B).  
 No significant difference in cumulative release of LDH or CK was observed between 
the groups. The cumulative release of these cardiac enzymes during the first 48 hours in 
patients having high anti-PCh IgM on admission was higher than that in the patients with low 
levels of anti-PCh IgM (Table 1 and figure 5 D, E), although the difference between the 
groups did not reach a statistical significance. In patients without a previous infarction infarct, 
size can also be measured from the electrocardiographic criteria, as indicated by the Selvester 
score. Twenty-four patients could be evaluated in this way. There was no difference in 
Selvester score of patients on admission with high or low levels of anti-apo IgM on admission 
(figure 5C). However, the score was significantly higher in patients with high levels of 
circulating anti-PCh IgM on admission, as compared to those with low levels (figure 5F).  
     IgM level
Marker 
Low  
anti-apo IgM 
High  
anti-apo IgM 
Low 
anti-PCh IgM 
High 
anti-PCh IgM 
LDH (U/L) 552.9 ±85.9 (n=22) 
524.5 ±80.1 
(n=23) 
P=0.81 462.8 ±66.7 
(n=23) 
617.4 ±94.6 
(n=22) 
P=0.19 
CK (U/L) 595.4 ±114.4 (n=22) 
566.3 ±82.7 
(n=21) 
P=0.84 521.4 ±77.5 
(n=21) 
638.2 ±116.4 
(n=22) 
P=0.41 
ECG  
(selvester 
score) 
28.6 ±3.2 
(n=13) 
27.6 ±2.9 
(n=11) 
P=0.81 23.2 ±3.1 
(n=11) 
32.3 ±2.5 
(n=13) *P=0.03 
Table 1: Relation of anti-apo IgM or anti-PCh IgM on admission to cardiac markers. Anti-
apo IgM levels were determined with apoptotic Jurkat cells and anti-PCh IgM on admission 
was determined by ELISA. Patients with low (<median) or high (>median) levels of anti-apo 
IgM or anti-PCh IgM were compared regarding cumulative concentration over 48 hours of 
creatine kinase (CK), lactate dehydrogenase (LDH) and their electrocardiographic (ECG) 
score. Data are given as mean value ± sem, and the difference between groups was analyzed 
with two-tailed Student’s t test when they appeared to be normally distributed.  
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Figure 5: Relation between apo-IgM, anti-PCh IgM and infarction size. (A, B, C): Levels of 
anti-apo IgM were measured with apoptotic Jurkat cells and expressed as MFI. Patients were 
said to have low or high levels when they had levels below or above, respectively, the median 
of the group. Electrocardiographic (ECG) results evaluated by cumulative release values of 
cardiac enzyme over 48 hours LDH (A) and CK (B) expressed as units per litre (U/L) and the 
Selvester score (C), and A similar analysis was made for anti-PCh IgM (D, E, and F). Data 
were analysed with Student’s t test. ns=non significant, *P<0.05.  
Relation of anti-apo IgM or anti-PCh IgM with post-infarct inflammatory response
A number of parameters including the acute phase proteins CRP and sPLA2, the cytokines 
IL6 and IL8, and activated complement fragments C4b/c and C3b/c, were determined to 
assess the inflammatory response in the patients. The cumulative concentration of the acute 
phase protein, sPLA2, over 48 hours after admission was comparable between patient groups 
having low or high levels of anti-apo IgM. However, the patients with increased circulating 
anti-PCh IgM on admission had a significant increase in their sPLA2 concentration when 
compared to patients with lower anti-PCh IgM (1031 μg/L ±175 versus 860 μg/L ±308, 
P=0.03, respectively; Table 2). Pro-inflammatory cytokines IL6 and IL8 concentrations 48 
hours after admission were comparable in patients having anti-apo IgM values or anti-PCh 
IgM below or above the median values (Table 2). The cumulative concentration of CRP over 
the 48 hours following admission was increased in the patients having both anti-apo IgM and 
anti-PCh IgM above the median values but did not reach a statistical significance (88 mg/L ± 
16 versus 149 mg/L ± 36, p=0.12, in patients with low or high anti-apo IgM, respectively, and 
101 mg/L ± 22 versus 146 mg/L ± 34, p=0.26, in patients with low and high anti-PCh IgM, 
respectively, mean ± sem). Similarly, the activated complement fragments, C4b/c and C3b/c 
48 hours after admission were comparable between patients and controls (Table 2). 
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Table 2: Relation of anti-PCh IgM on admission to inflammatory markers. Anti-apo IgM 
levels were determined with apoptotic Jurkat cells and anti-PCh IgM on admission was 
determined by ELISA. Patients with low (<median) and high levels of anti-apo IgM or anti-
PCh IgM (>median) were then compared regarding cumulative concentration over 48 hours 
of sPLA2, CRP, complement activated products (C4b/c and C3b/c) and cytokines IL6 and IL8. 
Data are given as mean value ± sem, and were analysed with two-tailed Student’s t test as 
they appeared to be normally distributed. *P<0.05 was considered significant.  
Discussion 
Recently, the role of IgM antibodies in cardiovascular disease has received considerable 
attention. It has been shown to play a role in the course of atherosclerosis [28;29], although 
their function has not been completely elucidated. Furthermore, our own studies show that 
IgM antibodies localize in infarcted human myocardium together with activated complement 
and CRP [13]. Co-localization with CRP, which can bind to PCh, suggests this IgM in 
infarcted myocardium in part is directed against PCh. Interestingly, IgM against PCh can bind 
to apoptotic cells [16]. In the present study, we measured IgM binding to apoptotic cells, as 
well as anti-PCh IgM in patients with AMI and found that levels of the latter antibodies on 
admission were related to the post-infarct response as well as to infarct size. 
 Though anti-PCh IgM has been found to bind to apoptotic cells [16;30], competition 
experiments with fluid-phase PCh indicate that not all IgM binding to these cells is directed 
against PCh [31]. Hence, to cover other specificities of IgM binding to apoptotic cells, we 
developed an assay in which apoptotic Jurkat cells are used as solid phase antigen and IgM 
bound to the cells is detected with FACS. The variability of levels of the IgM binding in this 
assay, in time was limited in healthy individuals (see figure 2) indicating a limited variation of 
           IgM 
level
Marker 
Low  
anti-apo IgM 
High  
anti-apo IgM 
Low 
anti-PCh IgM 
High 
anti-PCh IgM 
sPLA2 (ȝg/L) 943.8 ±316.0 (n=22) 
943.3 ±180.1 
(n=23) P=0.46 
860.7 ±308.1 
(n=23) 
1031.0 ±175.1 
(n=22) *P=0.03 
CRP (mg/L)  87.6 ±15.5 (n=22) 
148.5 ±35.5 
(n=22) P=0.12 
100.7 ±21.7 
(n=23) 
145.9 ±33.5 
(n=21) P=0.26 
C4b/c 
(nmol/L) 
101.2 ±20.6 
(n=22) 
136.5 ±33.48 
(n=23) P=0.38 
117.2 ±20.6 
(n=22) 
125.3 ±35.4 
(n=22) P=0.85 
C3b/c 
(nmol/L) 
156.7 ±44.5 
(n=22) 
278.9 ±225.0 
(n=22) P=0.35 
152.7 ±44.5 
(n=22) 
288.4 ±224.6 
(n=22) P=0.39 
IL6 (ng/L) 11.2 ±4.5 (n=22) 
10.1 ±2.7 
(n=23) P=0.33 
11.8 ±4.9 
(n=22) 9.7 ±2.0 (n=22) P=0.07 
IL8 (ng/L) 
12.1 ±2.1 
(n=19) 9.1 ±2.1 (n=22) P=0.30 
12.9 ±2.3 
(n=21) 8.1 ±1.7 (n=22) P=0.09 
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levels in individuals over time. Notably, in an earlier study we have also observed a similar 
limited variation of levels of anti-PCh IgM over time [22].  
 Levels of IgM binding to apoptotic cells at first glance were lower in the patients than 
in the healthy controls. However, as patients with AMI receive (intravenous) fluid infusions, 
we decided to correct levels for hemodilution by calculating the ratio to IgM. Indeed ratios of 
anti-apo IgM and total IgM appeared to be similar in patients versus healthy controls. Hence, 
these data did not support the possiblity that binding of this IgM to the ischemic myocardium 
had resulted in lower levels in the circulation. In contrast, levels of anti-PCh IgM, even when 
corrected for total IgM, were significantly lower in the patients on admission as compared to 
levels in healthy controls. Presumably this different behaviour of anti-PCh IgM versus anti-
apo IgM reflects that absolute levels of the former are lower than those of the latter, making 
anti-PCh IgM a more sensitive parameter in case of consumption. Preliminary experiments 
indeed indicate that anti-PCh IgM constitutes less than 1% of total IgM (N. Diaz Padilla, 
unpublished observation). Furthermore, we did not observe differences in anti-apo IgM or 
anti-PCh IgM, corrected for total IgM, on admission versus after 48 hours. In another study 
we observed in patients deceased after AMI that IgM binding to ischemic cardiomyocytes, 
appears in the infarcted myocardium approximately 24 hours after the occlusion of a coronary 
vessel as based on pathological criteria [13]. Therefore, we expected a further decrease of 
anti-PCh IgM in the patients with AMI during the first 48 hours after admission, but this was 
not observed. Further studies should reveal whether increased production of anti-PCh IgM has 
masked a decrease of levels due to localization in the infarcts.  
 Several studies have shown significant changes in plasma IgM and IgG levels upon 
tissue injury for examples in case of burns [32]. In contrast, we found no significant change of 
anti-apo IgM or anti-PCh IgM levels in patients with AMI during the first 48 hours. Though 
these data do not exclude that also AMI may induce an immunoglobulin response, such a 
response at least does not seem to occur within the observation period. Furthermore, similarity 
in levels on admission and after 48 hours, indicate that the analysis of levels on admission was 
not blurred by ongoing responses. Therefore, we decided to analyse whether patients with 
high levels on admission had a more intense inflammatory response than patients with lower 
levels of anti-apo or anti-PCh IgM.  
 Though patients with high levels of anti-apo IgM or anti-PCh IgM on admission had 
similar levels of IL6 and IL8 as patients with low levels (Table 2), their concentrations of 
CRP, sPLA2 and of complement activation products tended to increase. When the analysis 
was limited to the anti-PCh IgM specificity alone, sPLA2 concentrations were significantly 
higher in the group above median value. These data suggest that IgM with specificity for PCh 
is associated with the inflammatory response in patients with AMI. 
 Infarct size is determined by a number of parameters including localization of the 
occlusion, collateral circulation, treatment, and others [33;34]. Therefore, we did not expect to 
find an association between levels of anti-apo IgM or anti-PCh IgM and parameters of cardiac 
damage in this limited number of patients. Yet, patients with anti-PCh IgM on admission 
tended to have higher cumulative release of CK and LDH. Assessment of infarction size using 
electrographical score is only possible in case of a first infarction. Among patients with a first 
infarction, those who had higher anti-PCh IgM had a significantly higher Selvester score on 
admission than those with lower anti-PCh IgM. IgM is a known activator of complement and 
has been shown to bind apoptotic surfaces, in particular to phosphorylcholine [16] and 
activate complement [15]. Taken together, these observations would suggest that IgM 
antibodies particularly anti-PCh IgM may participate in the activation or amplification of the 
inflammation after AMI via the activation of complement. 
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 Anti-PCh IgM can bind to apoptotic cells [16;28]. Competition experiments with 
soluble phosphorylcholine, however, indicate that not all IgM directed against apoptotic cells 
is against PCh [31]. Our results do not point to a role of anti-apoptotic cell IgM with other 
specificities in myocardial infarction. Yet it should be noted that a relationship between 
plasma levels of this IgM and inflammatory responses and infarct size only become clear 
when plasma levels are limiting. Thus, our data do not definitely rule out a role for IgM 
binding to apoptotic cells in local inflammatory reactions ensuing in the infarcted 
myocardium.  
 In conclusion, levels of anti-PCh IgM in patients with AMI are associated with a 
somewhat more intense inflammatory response and a larger infarct size. These data fit with 
the hypothesis that this IgM species by enhancing inflammatory damage to the heart during 
infarction, may contribute to infarction size.  
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CHAPTER 7 
Summarizing discussion 
 Ischemia-reperfusion injury (IRI) is an important pathophysiological event that occurs 
in many clinical conditions, ranging from surgery (cardiovascular bypass, abdominal 
aneurysm repair, transplantation), acute artery occlusion (stroke, gut ischemia, acute 
myocardial infarction (AMI)) to hemorrhagic shock. IRI may increase the morbidity and 
mortality of patients undergoing such events [1-3]. Complement activation is thought to be an 
important mediator in IRI, because complement inhibition and complement deficiency 
considerably attenuate irreversible injury [4-7]. However, the specific complement pathways 
involved remain unclear. All three complement pathways: the classical, the alternative, and 
the mannose-binding lectin (MBL)-dependent pathway may be involved in the development 
of IRI, depending on the model, the tissue, and the time course of inflammation [6,8-10]. This 
thesis focuses on the role of CRP and natural IgM Ab in tissue damage after ischemia and 
reperfusion. Ischemia leads to the exposition of “altered phospholipids” and neoantigens on 
the damaged tissue that can be recognized by C-reactive protein (CRP) or/and natural IgM 
antibody (natural IgM). The binding of both plasma proteins to ligands on the damaged tissue 
is followed by complement activation [11-15].
Complement activation by rat CRP 
Because important biological functions of proteins are generally conserved among species, 
and because CRP has a very stable phylogenetic conservation of amino-acid sequence, subunit 
composition and binding specificity for phosphorylcholine (Pc), the role of CRP in mediating 
complement activation is likely to be similar in all animals [reviewed in 16].
 To test this idea, we re-evaluated the capability of rat CRP to activate the rat 
complement system, as described in the Chapter 2. Complement activation was investigated in 
solid and fluid-phase systems. In the solid phase, rat and human CRP were fixed to ELISA 
plates and incubated with human and rat plasma. Dose-dependent binding of human and rat 
activated complement factors (C3b/c and C4b/c) were observed to human CRP and rat CRP. 
The generation of rat CRP-complement complexes (specific markers for CRP-dependent 
complement activation), after incubation of rat plasma with CRP ligands, i.e. C-
polysaccharide of pneumococci (CPS) and lysophosphatidylcholine (Lyso-Pc), demonstrated 
this ability of rat CRP in the fluid phase. Furthermore, it was shown that complement 
activation by rat CRP occurs through the classical pathway, because it binds to C1q (both 
human and rat C1q). Next to these in vitro studies, we investigated whether CRP could 
activate complement in rat models of ischemia-reperfusion. Indeed, CRP-C3 complexes were 
detected in plasma in models for hind-limb and liver ischemia-reperfusion [17] and bacterial 
meningitis (data not shown). These findings together suggest that rat CRP can also activate 
autologous complement in vivo.
 The discrepancy between our observations and previous findings that reported that rat 
CRP was unable to activate complement, is presumably a result of the use of different CRP 
ligands and methods to assess complement activation. Whereas we used a sensitive assay for 
the quantitation of CRP-complement complexes, in combination with other assays, and CPS 
and Lyso-Pc as ligands, de Beer et al. [18] used crossed immunoelectrophoresis, which is less 
sensitive than our ELISAs, and only CPS as CRP ligand. 
 A requirement for the activation of complement by CRP is that the pentraxin must be 
clustered into dimers or trimers, which is achieved when it is bound to suitable ligands, such 
as Pc in membranes of damaged cells [12,19-21]. Chapter 3 reports that although rat CRP levels 
increase upon estrogen replacement, this does not result in complement activation. Two 
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different doses of 17ȕ-estradiol were administered to ovariectomized F-344 rats. The plasma 
CRP levels increased after estrogen administration. The fact that this increase did not result in 
complement activation in this model is consistent with the idea that suitable CRP ligands are 
also required. 
Role of CRP and natural IgM in a rat model of intestinal IRI 
There is accumulating evidence that complement activation by CRP and natural IgM Ab are 
important contributors to IRI. In mouse models of ischemia-reperfusion, a role of IgM in this 
process has been postulated [6,22]. In humans, both IgM and CRP play a role in complement 
activation after AMI [1,23,24]. In rats, CRP-mediated complement activation seems to be 
involved in the increase of infarct size in rats subjected to coronary artery ligation in a model 
of AMI [25]. The relative contribution of both proteins in the development of IRI in rats is still 
not fully elucidated. 
 Chapter 4 deals with the role of CRP, IgM and anti-Pc IgM in complement activation 
in a rat model of intestinal IRI. The effect of C1-inhibitor on inflammatory mediators was 
evaluated. Rats were subjected to 1 h of superior mesenteric artery occlusion and 3 h of 
reperfusion. Intestinal injury and myeloperoxidase activity were increased following IR 
compared to the sham animals. Ischemia and reperfusion results in significant deposition of 
CRP, IgM and complement on injured intestinal tissue. A better correlation was found 
between CRP/complement than IgM/complement deposition, which suggests that CRP could 
be the dominant complement activator in this model. It was supported by the positive 
correlation between the levels of C4b/c and CRP measured in intestinal homogenates. We 
showed that C1-Inh reduces C4b/c generation as measured in the homogenates. However, 
significant decrease of activated C3 deposition in the injured intestines was not observed 
 Taken together; these findings indicate that in animals with high CRP levels, as seen in 
rats, CRP and not natural IgM Ab is the dominant complement activator during ischemia and 
reperfusion. We suggest that therapeutic inhibition of the binding of CRP and IgM to 
damaged tissue may be a new anti-inflammatory therapy to decrease mortality rates in clinical 
conditions associated with IRI [26]. Recently, it has been shown, that neo epitopes expressed 
after ischemia and reperfusion in rats are not only recognized by CRP and IgM but also by 
MBL leading to the lectin pathway activation of the complement [27]. Further studies on the 
relative contribution of the classical vs. MBL pathway are needed to elucidate the role of both 
pathways.  
Anti-Pc IgM in healthy donors and during acute phase response 
Natural IgM Ab binds Pc (anti-Pc IgM) on microorganisms and on altered-self molecules, 
such as oxidized phospholipids. These Pc molecules are present in oxidized lipoproteins and 
in the outer leaflet of the plasma membrane of apoptotic and necrotic cells [28-30]. The binding 
of anti-Pc IgM to their ligands is followed by complement activation [31]. Because of these 
shared abilities with CRP (binding to Pc and complement activation), we propose that anti-Pc 
IgM could be, like CRP, a cardiovascular risk factor [12,32-34]. Recently, it has been shown that 
anti-Pc IgM blocks the progression of atherosclerosis by inhibiting the uptake of oxLDL by 
scavenger receptors on macrophages [35,36]. Therefore, based on the proposed anti-
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atherosclerotic role of anti-Pc IgM, studies on the relationship between circulating levels of 
anti-Pc IgM and the risk of cardiovascular disease deserve further investigation.  
 We developed and validated an ELISA system for the quantitation of anti-Pc IgM Abs. 
As described in chapter 5, levels of anti-Pc IgM in healthy donors differed by more than 100-
fold, but there was no relationship between these levels and age. Our data do not support the 
notion that anti-Pc IgM in humans is increased in atherosclerosis, since in that case, some 
relationship between plasma levels and age would be expected.  Because no correlation 
between plasma CRP and anti-Pc IgM was found, we speculate that IgM and CRP constitute 
two independent mechanisms involved in the elimination of injured cells. Future studies on 
anti-Pc IgM should delineate its role in human diseases such as cardiovascular disease.  
 To test the hypothesis that anti-Pc IgM can bind, as CRP [12], to neoantigens expressed 
on necrotic or apoptotic cells, circulating levels of anti-Pc IgM were quantified in patients 
with skin cancers treated by isolated limb perfusion with tumor necrosis factor-Į. Most of 
these patients exhibited massive death of both malignant cells and endothelial cells of the 
tumour vasculature [37]. Following this procedure, a significant decrease of circulating anti-Pc 
IgM relative to total IgM Ab was found. This decrease is in agreement with the notion that 
anti-Pc IgM can bind to phospholipids exposed on damaged cells.  
 The levels of circulating anti-Pc IgM were measured also in plasma samples from 
patients with AMI, as described in chapter 6. The measurement was done in samples obtained 
on admission (t0) and 48 hours thereafter (t48). In order to restore blood flow to the affected 
area, 70 % of the patients were treated at admission with thrombolytic agents and 20% with 
percutaneous transluminal coronary angioplasty. The relationship between anti-Pc IgM, 
inflammatory mediators and infarct size as assessed with electrocardiography was further 
analyzed. 
 The levels of anti-Pc IgM were significantly lower in patients with AMI (t0) than in 
healthy donors. This may suggest that in the patients circulating anti-Pc IgM is removed from 
the circulation and deposited in the infarcted myocardium tissue. At t48 the blood circulation 
was restored again. Because of this restored circulation, we expected to find more anti-Pc IgM 
deposition and therefore lower anti-Pc titers in the plasma. However, no difference in anti-Pc 
IgM levels between t0 and t48 was observed. Krijnen et al. [23] have shown that IgM Abs are 
deposited in ischemic infarcts, 24 h after the occlusion of a coronary artery. These 
investigators did not measure the IgM levels in plasma. In our experiments, a possible 
explanation for the absence of decreased anti-Pc IgM levels in plasma maybe attributed to be 
increased production of IgM, including anti-Pc IgM.  
 Nevertheless, levels of anti-Pc IgM on admission correlated with the levels of the 
inflammatory mediator, secretory phospholipase A2 (sPLA2) and with the infarct size. IgM is 
a known activator of complement after binding to apoptotic surfaces like Pc. Taken together, 
these observations suggest that anti-Pc IgM participate in amplification of inflammation after 
AMI via activation of complement, and in that way increase the cardiac damage. 
Concluding remarks 
This thesis describes that CRP in rats is able to activate the classical pathway of the 
complement system. This means that rats are suitable animals to study the CRP-mediated 
complement activation after tissue damage. The relative contributions of CRP and IgM to 
activation of the complement system varies between species. In a rat model of intestinal 
ischemia-reperfusion, CRP (basal level about 500 mg/L) was shown to be the dominant 
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complement activator. The administration of anti-Pc IgM Abs in rat models of ischemia-
reperfusion may be used to elucidate its potential impact. The decrease in plasma anti-Pc IgM 
levels found under conditions of excessive cell death, and the increased production of pro-
inflammatory mediators, is in agreement with the notion that these Abs bind to apoptotic and 
necrotic cells. Thus, anti-Pc IgM amplifies inflammation and likely participates in the 
clearance of cell debris. The correlation found between levels of anti-Pc IgM, sPLA2 and 
infarct size supports the notion that these Abs contribute to cell damage. Anti-Pc IgM levels 
were measured in healthy donors to study the variability in the population. Our data do not 
support the notion that these Abs are related with the process of atherogenesis, because no 
correlation between level and age was found. Further prospective studies on anti-Pc IgM in 
the healthy population should be performed to delineate their role in atherogenesis.  
 All together, CRP as well as anti-Pc IgM can be involved in processes following tissue 
damage. Clearing of apoptotic cells is an example of this involvement. Binding of CRP and 
IgM to damaged tissue can lead to an increased inflammation. Development of strategies to 
prevent binding of CRP and/or IgM can be useful to prevent further activation of effector 
mechanisms. 
Diagram illustrating the proposed role of CRP, anti-Pc IgM and complement mediating 
ischemia and reperfusion injury on a cell membrane. The flip-flop of the membrane, 
oxidation of the phospholipids by oxygen radicals and hydrolysis by phospholipases A2 (not 
shown) after an ischemic insult generate binding sites, i.e. Pc, on the membranes. CRP and 
IgM bind to Pc. C1q binding to CRP and IgM triggers the complement cascade. Because 
damaged tissues lack the regulatory molecules that in normal tissues prevent excessive 
complement activation, complement might be completely activated up to the formation of the 
membrane attack complex (MAC). MAC leads to pore formation and the cell are irreversibly 
damaged.  
109
Reference list 
1. Nijmeijer R., Krijnen P.A., Assink J., Klaarenbeek M.A., Lagrand W.K., Veerhuis R., 
    Visser C.A., Meijer C.J., Niessen H.W., & Hack C.E. C-reactive protein and complement           
    depositions in human infarcted myocardium are more extensive in patients with reinfarction       
    or upon treatment with reperfusion. Eur.J.Clin.Invest. 2004. 34: 803-810. 
2.  Khalil A.A., Aziz F.A., & Hall J.C. Reperfusion injury. Plast.Reconstr.Surg. 2006. 117:   
     1024-1033. 
3.  Homer-Vanniasinkam S., Crinnion J.N., & Gough M.J. Post-ischaemic organ dysfunction:   
     a review. Eur.J.Vasc.Endovasc.Surg.1997. 14: 195-203. 
4. de Zwaan C., Kleine A.H., Diris J.H., Glatz J.F., Wellens H.J., Strengers P.F., Tissing M.,  
    Hack C.E., Dieijen-Visser M.P., & Hermens W.T. Continuous 48-h C1-inhibitor treatment,   
    following reperfusion therapy, in patients with acute myocardial infarction. Eur.Heart J.  
    2002. 23: 1670-1677. 
5. Karpel-Massler G., Fleming S.D., Kirschfink M., & Tsokos G.C. Human C1 esterase 
    inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. 
    J.Surg.Res.2003. 115: 247-256. 
6. Weiser M.R., Williams J.P., Moore F.D., Jr., Kobzik L., Ma M., Hechtman H.B., & Carroll 
    M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody  
    and complement. J.Exp.Med. 1996. 183: 2343-2348. 
7. Yamada K., Miwa T., Liu J., Nangaku M., & Song W.C.  Critical protection from renal 
    ischemia reperfusion injury by CD55 and CD59. J.Immunol. 2004.  172: 3869-3875. 
8. Ciurana C.L.F.C.E.H. Molecular mechanisms of complement activation during ischaemia   
     and reperfusion. In: Yearbook of Intensive Care and Emergency Medicine. 2002. (ed.   
     J. J.-L.Vincent), p. 39-50 Springer, Berlin . 
9. Collard C.D., Vakeva A., Morrissey M.A., Agah A., Rollins S.A., Reenstra W.R., Buras    
    J.A., Meri S., & Stahl G.L. Complement activation after oxidative stress: role of the lectin 
    complement pathway. Am.J.Pathol. 2000. 156: 1549-1556. 
10. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., & Zhao H. Role for the  
      alternative complement pathway in ischemia/reperfusion injury. Am.J.Pathol. 2003. 162: 
      449-455. 
11. Chan R.K., Ding G., Verna N., Ibrahim S., Oakes S., Austen W.G., Jr., Hechtman H.B., & 
      Moore F.D., Jr. IgM binding to injured tissue precedes complement activation during 
      skeletal muscle ischemia-reperfusion. J.Surg.Res. 2004. 122: 29-35. 
12. Gershov D., Kim S., Brot N., & Elkon K.B. C-Reactive protein binds to apoptotic cells, 
      protects the cells from assembly of the terminal complement components, and sustains an 
      antiinflammatory innate immune response: implications for systemic autoimmunity. 
      J.Exp.Med. 2000.  192: 1353-1364. 
110
13. Hack C.E., Wolbink G.J., Schalkwijk C., Speijer H., Hermens W.T., & van den B.H. A 
      role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. 
      Immunol.Today.1997. 18: 111-115. 
14. Krijnen P.A., Nijmeijer R., Meijer C.J., Visser C.A., Hack C.E., & Niessen H.W.  
      Apoptosis in myocardial ischaemia and infarction. J.Clin.Pathol. 2002. 55: 801-811. 
15. Ogawa S., Clauss M., Kuwabara K., Shreeniwas R., Butura C., Koga S., & Stern D.  
      Hypoxia induces endothelial cell synthesis of membrane-associated proteins.  
      Proc.Natl.Acad.Sci.U.S.A.1991. 88: 9897-9901. 
16. Baltz M.L., de Beer F.C., Feinstein A., Munn E.A., Milstein C.P., Fletcher T.C., March 
      J.F., Taylor J., Bruton C., Clamp J.R., Davies A.J., & Pepys M.B. Phylogenetic aspects of 
     C-reactive protein and related proteins. Ann.N.Y.Acad.Sci. 1982. 389: 49-75. 
17. Heijnen B.H., Straatsburg I.H., Padilla N.D., Van Mierlo G.J., Hack C.E., & Van Gulik 
      T.M. Inhibition of classical complement activation attenuates liver ischaemia and  
      reperfusion injury in a rat model. Clin.Exp.Immunol. 2006. 143: 15-23. 
18. de Beer F.C., Baltz M.L., Munn E.A., Feinstein A., Taylor J., Bruton C., Clamp J.R., & 
      Pepys M.B. Isolation and characterization of C-reactive protein and serum amyloid P 
      component in the rat. Immunology. 1982. 45: 55-70. 
19. Thompson D., Pepys M.B., & Wood S.P. The physiological structure of human C-reactive 
      protein and its complex with phosphocholine. Structure. 1999. 7: 169-177. 
20. Volanakis J.E. Complement activation by C-reactive protein complexes.   
      Ann.N.Y.Acad.Sci.1982. 389: 235-250. 
21. Volanakis J.E. Human C-reactive protein: expression, structure, and function.     
      Mol.Immunol. 2001.  38: 189-197. 
22. Williams J.P., Pechet T.T., Weiser M.R., Reid R., Kobzik L., Moore F.D., Jr., Carroll 
      M.C., & Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and  
      complement. J.Appl.Physiol. 1999. 86: 938-942.  
23. Krijnen P.A., Ciurana C., Cramer T., Hazes T., Meijer C.J., Visser C.A., Niessen H.W., & 
      Hack C.E.  IgM colocalises with complement and C reactive protein in infarcted human 
      myocardium. J.Clin.Pathol. 2005. 58: 382-388. 
24. Nijmeijer R., Lagrand W.K., Lubbers Y.T., Visser C.A., Meijer C.J., Niessen H.W., & 
      Hack C.E. C-reactive protein activates complement in infarcted human myocardium. 
      Am.J.Pathol. 2003. 163: 269-275. 
25. Griselli M., Herbert J., Hutchinson W.L., Taylor K.M., Sohail M., Krausz T., & Pepys 
      M.B. C-reactive protein and complement are important mediators of tissue damage in 
      acute myocardial infarction. J.Exp.Med. 1999.190: 1733-1740. 
26. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., 
      Hawkins P.N., Myers R.M., Smith M.D., Polara A., Cobb A.J., Ley S.V., Aquilina J.A., 
111
      Robinson C.V., Sharif I., Gray G.A., Sabin C.A., Jenvey M.C., Kolstoe S.E., Thompson 
      D., & Wood S.P. Targeting C-reactive protein for the treatment of cardiovascular disease. 
      Nature. 2006. 440: 1217-1221. 
27. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., Solomon S.D., 
       Ezekowitz R.A., & Stahl G.L. Mannose-binding lectin is a regulator of inflammation that 
       accompanies myocardial ischemia and reperfusion injury. J.Immunol. 2005. 175: 541-
       546. 
28. Chang M.K., Bergmark C., Laurila A., Horkko S., Han K.H., Friedman P., Dennis E.A., & 
      Witztum J.L. Monoclonal antibodies against oxidized low-density lipoprotein bind to 
      apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that 
      oxidation-specific epitopes mediate macrophage recognition. Proc.Natl.Acad.Sci.U.S.A. 
      1999. 96: 6353-6358. 
29. Ciurana C.L. & Hack C.E. Competitive binding of pentraxins and IgM to newly exposed 
      epitopes on late apoptotic cells. Cell Immunol. 2006. 239: 14-21.  
30. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., &  
      Witztum J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis,  
      apoptotic clearance, and protective immunity. J.Clin.Invest.2000 105: 1731-1740. 
31. Kim S.J., Gershov D., Ma X., Brot N., & Elkon K.B. I-PLA(2) activation during apoptosis 
      promotes the exposure of membrane lysophosphatidylcholine leading to binding by  
      natural immunoglobulin M antibodies and complement activation. J.Exp.Med. 2002. 196: 
      655-665. 
32. Black S., Kushner I., & Samols D. C-reactive Protein. J.Biol.Chem. 2004. 279: 8487-
      48490. 
33. Niessen H.W. & Hack C.E. C-reactive protein and the risk of cardiovascular mortality. 
      Am.J.Med. 2003  114: 241-242. 
34. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., & Hennekens C.H. Inflammation, 
      aspirin, and the risk of cardiovascular disease in apparently healthy men. N.Engl.J.Med. 
      1997. 336: 973-979. 
35. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., 
      Palinski W., Witztum J.L., & Silverman G.J. Pneumococcal vaccination decreases  
      atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae 
      and oxidized LDL. Nat.Med. 2003. 9: 736-743. 
36. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., 
      Friedman P., Dennis E.A., Curtiss L.K., Palinski W., & Witztum J.L. Monoclonal  
      autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein 
      adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J.Clin.Invest. 
      1999.103: 117-128. 
112
37. Van Ginkel R.J., Hoekstra H.J., Eggermont A.M., Pras E., & Koops H.S. Isolated limb 
      perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. 
      Arch.Surg. 1996. 131: 672-674.
113

    Samenvatting 
Ischemie-reperfusie-schade (IRS) is een belangrijk pathofysiologisch verschijnsel dat 
optreedt bij vele klinische condities, zoals chirurgische interventies (bypass-operatie, 
transplantatie), acute arteriële occlusie (darmischemie, acuut myocardinfarct) en 
hypovolemische shock. IRS kan de morbiditeit en de mortaliteit bij patiënten met deze 
aandoeningen verhogen. Vermoedelijk speelt complement activatie een belangrijke rol bij 
IRS, omdat remming van de complementactivatie en ook complementdeficiëntie een 
aanzienlijke afname van de irreversibele schade geeft. De specifieke mechanismen zijn echter 
nog onduidelijk. Er zijn drie complement activatie-routes bekend, te weten: de klassieke-, de 
alternatieve- en de mannose-bindend lectine (MBL)-afhankelijke route. Afhankelijk van de 
aandoening, het weefsel en de duur van de ontsteking kunnen alle drie activatie routes een rol 
spelen in het ontstaan van IRS. Dit proefschrift richt zich op de rol van de binding van CRP 
en natuurlijke IgM antistoffen aan beschadigd weefsel, in het bijzonder na ischemie en 
reperfusie. Ischemie leidt tot blootstelling van “veranderde fosfolipiden” en neoantigenen op 
cellen in het beschadigde weefsel, en deze kunnen vervolgens herkend worden door de 
plasma-eiwitten C-reactief protein (CRP) en/of door natuurlijke IgM antistoffen. De binding 
van beide plasma-eiwitten aan het beschadigde weefsel wordt gevolgd door 
complementactivatie.  
Complementactivatie door ratten-CRP 
Eiwitten met essentiële biologische functies zijn meestal geconserveerd tussen verschillende 
diersoorten. CRP is een sterk geconserveerd eiwit op basis van aminozuur-sequentie, 
subunitsamenstelling en binding aan phosphorylcholine (Pc). Dit suggereert dat CRP in 
verschillende zoogdieren een vergelijkbare rol speelt in complementactivatie. 
 Hierom hebben we opnieuw het vermogen van ratten-CRP onderzocht om het 
complementsysteem te activeren, zoals beschreven in hoofdstuk 2. Complementactivatie werd 
onderzocht in vaste-fase en vloeibare-fase systemen. In vaste-fase werd ratten-en humaan 
CRP gefixeerd op ELISA platen en geïncubeerd met ratten-en humaan serum. Dosis-
afhankelijke binding van geactiveerde ratten-en humane complement-eiwitten C3b/c en C4b/c 
aan ratten-en humaan CRP werd vastgesteld. In de vloeibare-fase opzet werd CRP 
geïncubeerd met zijn liganden C-polysacharide van pneumococci (CPS) en 
lysophosphatidylcholine (Lyso-Pc). De vorming van CRP-complement complexen in dit 
systeem demonstreerde CRP-afhankelijke complementactivatie. Bovendien werd vastgesteld 
dat complementactivatie door ratten-CRP verliep via de klassieke route omdat het C1q bindt, 
en dat ratten-CRP zowel ratten-als humaan C1q kan binden. Naast deze in vitro studies 
hebben we in een rattenmodel van IRS bekeken of CRP het complementsysteem kan 
activeren. In die studie hebben we aan kunnen tonen dat er CRP-C3 complexen gevormd 
worden tijdens in ischemie en reperfusie van de achterpoot en van de lever, en in 
experimentele bacteriële meningitis. Deze gegevens zijn een sterke indicatie dat autologe 
complementactivatie door ratten-CRP in vivo optreedt. 
 Een eerdere studie toonde geen complementactivatie aan door ratten-CRP. Deze 
eerdere studie gebruikte echter alleen CPS als ligand en gebruikte bovendien de minder 
gevoelige ‘crossed immunoelectrophoresis’ als meetmethode. Dit kan het verschil met onze 
studie verklaren. 
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 Een voorwaarde voor de activatie van complement door CRP is de aggregatie van 
CRP tot di- of trimeren. CRP aggregatie kan bewerkstelligd worden door binding aan 
geschikte liganden, zoals Pc in beschadigd weefsel. Hoofdstuk 3 beschrijft de invloed van 
oestrogenen op CRP-gemediëerde complementactivatie. Twee verschillende doseringen van 
17ȕ-estradiol capsules werden toegediend aan F-344 ratten na ovariëctomie. Het plasma-CRP 
niveau steeg na oestrogeentoediening, maar er werd geen complementactivatie gedetecteerd. 
Dit geeft aan dat stijging van het CRP gehalte niet tot complementactivatie leidt als niet ook 
de geschikte liganden gelijktijdig gegenereerd worden. 
Rol van CRP en natuurlijk IgM in een rattenmodel voor intestinale IRS 
Er zijn vele aanwijzingen dat complementactivatie door CRP en natuurlijke IgM antistoffen in 
belangrijke mate bijdragen aan IRS. In muizenmodellen van IRS is een rol voor IgM 
gepostuleerd. In de mens is gevonden dat zowel IgM als CRP een rol spelen bij 
complementactivatie na acuut myocardinfarct. In een rattenmodel voor acuut myocardinfarct 
lijkt CRP-gemediëerde activatie gecorreleerd aan de grootte van het infarct na 
kransslagaderligatie. Echter, de relatieve bijdrage van beide eiwitten in de ontwikkeling van 
IRS in ratten is nog steeds niet volledig opgehelderd. 
 Hoofdstuk 4 gaat in op de rol van CRP, IgM en anti-Pc IgM in complementactivatie in 
een rattenmodel voor intestinale IRS. Het effect van C1 esteraseremmer op inflammatoire 
mediatoren wordt hierin beschreven. Ratten werden onderworpen aan een acute afsluiting van 
de arteria mesenterica superior gedurende 1 uur, gevolgd door een 3 uur durende reperfusie.  
 Intestinale schade en myeloperoxidaseactiviteit waren toegenomen gedurende 
ischemie en reperfusie, vergeleken met controledieren. Ischemie en reperfusie resulteerde in 
een significante depositie van CRP, IgM en complement op beschadigd intestinaal weefsel. 
De correlatie die gevonden werd tussen CRP en complement was sterker dan die tussen IgM 
en complement. Dat suggereert dat CRP mogelijk de dominante complement-activator is in 
dit model. Dit werd ondersteund door de positieve correlatie tussen C4b/c en CRP, gemeten in 
intestinale homogenaten. Wij toonden aan dat C1- esteraseremmer de C4b/c productie in 
intestinaal tissue blokkeert. We konden echter geen significante afname van C3 depositie in 
het beschadigde weefsel aantonen. 
 Alles tezamen suggeren deze resultaten dat in dieren met hoge CRP titers, zoals ratten, 
CRP de dominante complementactivator is gedurende IRS en niet natuurlijke IgM antistoffen. 
Therapeutische remming van de binding van CRP en IgM aan beschadigd weefsel kan een 
nieuwe anti-inflammatoire therapie worden. De morbiditeit en de mortaliteit in klinische 
condities geassocieerd met IRS kunnen hierdoor afnemen. Onlangs is in ratten aangetoond dat 
neo-epitopen die tot expressie komen na ischemie en reperfusie niet alleen worden herkend 
door CRP en IgM, maar ook door MBL, hetgeen leidt tot complementactivatie via de 
‘lectineroute’. Verdere studies aan de relatieve bijdrage van de MBL-route ten opzichte van 
de klassieke route zijn nodig om het belang van beide op te helderen. 
Anti-Pc IgM in gezonde donoren en gedurende de acute-fase respons 
Natuurlijke IgM antistoffen kunnen binden aan Pc op microorganismen en op veranderde 
eigen-antigenen zoals geoxideerde fosfolipiden. Deze worden gevonden op lipoproteinen en 
in het celmembraan van apoptotische en necrotische cellen. De binding van anti-Pc IgM aan 
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zijn liganden wordt, net als bij CRP, gevolgd door complementactivatie.  Recentelijk is 
vastgesteld dat anti-Pc IgM athereosclerose afremt. Door binding van anti-Pc IgM aan  
OxLDL wordt OxLDL niet meer herkend door de scavenger receptor op macrofagen en 
daardoor niet opgenomen. Omdat CRP en anti-Pc IgM beide binden aan Pc en beide 
complement kunnen activeren, stellen we voor om anti-Pc IgM, net als CRP, als risico factor 
voor cardiovasculaire aandoeningen te beschouwen. Echter, gezien de mogelijke anti-
arthereosclerotische rol van anti-Pc IgM, is meer onderzoek nodig naar de relatie tussen 
circulerende anti-Pc IgM titers en het risico van cardiovasculaire ziekte . 
 Er is een ELISA voor de kwantificering van anti-Pc IgM ontwikkeld en gevalideerd. 
Dit is beschreven in hoofdstuk 5. De anti-Pc IgM titers in gezonde donoren varieerde met 
meer dan een factor 100, maar was er geen relatie tussen titer en leeftijd. Onze data 
ondersteunen dus niet de gedachte dat humaan anti-Pc IgM verhoogd is in arthereosclerosis, 
omdat dan enige relatie met leeftijd verwacht zou worden. Er werd ook geen correlatie 
gevonden tussen plasma-CRP en anti-Pc IgM titers. Dit suggereert dat anti-Pc IgM en CRP 
twee aparte mechanismen vormen bij de eliminatie van beschadigde cellen. Het wordt vaker 
gezien dat essentiële biologische mechanismen op meer dan één manier gereguleerd worden, 
om het effect van ontsporingen te verkleinen. Vervolgstudies kunnen meer licht werpen op de 
rol van anti-Pc IgM antilistoffen in cardiovasculaire ziekten. 
 Om de hypothese te toetsen dat anti-Pc IgM, net als CRP kan binden aan neo-
antigenen die tot expressie komen op necrotische of apoptotische cellen, hebben we de anti-Pc 
IgM titers gemeten in patiënten met huidkanker die behandeld werden met tumor necrosis 
factor-Į in regionale perfusie. In de meeste van deze patiënten werd massale sterfte gemeten 
van zowel tumorcellen als endotheelcellen van de tumorvasculatuur. Tijdens deze procedure 
werd een significante afname van anti-Pc IgM gemeten, gerelateerd aan de totaal IgM titers. 
Deze afname kan verklaard worden doordat anti-Pc IgM bindt aan de beschadigde cellen en 
zo uit de circulatie verdwijnt. 
 De titers van circulerend anti-Pc IgM werden ook bepaald in plasma van patiënten met 
acuut myocardinfarct, zoals beschreven in hoofdstuk 6. De bepaling werd uitgevoerd in 
monsters verkregen bij opname in het ziekenhuis (t0) en 48 uur daar (t48). Om de 
bloedcirculatie in het aangedane weefsel te herstellen werden 70% van de patiënten 
behandeldeld met een thrombolyticum (stolsel-oplossend middel) en 20% werd behandeld 
met directe angioplastiek (PTCA of dotterprocedure). De correlatie werd bepaald tussen anti-
Pc IgM, inflammatoire mediatoren en de grootte van het infarct, gemeten met 
elektrocardiografie. De anti-Pc IgM titers in acuut myocardinfarct patiënten (t0) waren 
significant lager dan in de gezonde donoren. Dit suggereert dat de plasma titers van het anti-
Pc IgM lager worden door depositie van anti-Pc IgM in het aangedane weefsel. Op t48 is de 
bloedcirculatie weer hersteld en hierdoor zou nog meer depositie anti-Pc IgM kunnen 
optreden. We vonden echter geen additionele afname van anti-Pc IgM na 48 uur. Krijnen et 
al. hebben IgM-depositie gevonden in hartweefsel op 24 uur na afsluiting van een 
kransslagader. Ze hebben echter geen IgM gemeten in plasma. Een mogelijke verklaring voor 
het uitblijven van een verdere daling van anti-Pc IgM na herstel van de circulatie in onze 
experimenten is een verhoogde productie van anti-Pc IgM. Niettemin, anti-Pc IgM-titers bij 
ziekenhuisopname correleren met de ontstekings-mediator secretoroir  fosfolipase A2 (sPLA2) 
en met de grootte van het infarct. IgM is een bekende activator van het complementsysteem, 
met name door binding aan apoptotische oppervlakken die Pc epitopen bevatten. 
 Samengevat kan gesteld worden dat zowel CRP als anti-Pc IgM antistoffen betrokken 
kunnen zijn bij processen waarbij de integriteit van weefsel aangedaan is. In het geval van 
klaring van apoptotische cellen bijvoorbeeld, kunnen CRP en IgM antistoffen bijdragen aan 
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de verwijdering van dit soort materiaal. Wanneer de binding van CRP en IgM plaats vindt aan 
beschadigd weefsel kan dit leiden tot verdere versterking van ontsteking. In dit soort gevallen 
zou men graag strategieën willen ontwikkelen om de binding van CRP en IgM te blokkeren of 
de activatie van effectormechanismen te reduceren. 
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